Altering memory by affecting STAUFEN function

ABSTRACT

The present invention provides methods for screening a pharmaceutical agent for its ability to modulate long term memory formation, performance of a hippocampal-dependent cognitive task or STAUFEN function. The present invention also provides methods for modulating long term memory formation or performance of a hippocampal-dependent cognitive task by modulating staufen-dependent protein expression. The present invention further provides methods for treating a defect in long term memory formation associated with a defect in STAUFEN and methods for treating a defect in performance of a hippocampal-dependent cognitive task associated with a defect in STAUFEN.

RELATED APPLICATION(S)

This application is a continuation of International Application No.PCT/US2003/020125, which designated the United States and was filed Jun.25, 2003, published in English, which claims the benefit of U.S.Provisional Application No. 60/391,687, filed Jun. 25, 2002. The entireteachings of the above applications are incorporated herein byreference.

BACKGROUND OF THE INVENTION

Long term memory (LTM) involves induction of a cascade of geneexpression (Davis, H. P. and Squire, L. R., Psychol. Bull., 96:518-559(1984); Tully, T. et al., Cell, 79:35-47 (1994); Yin, J. C. et al.,Cell, 79:49-58 (1994); Yin, J. C. et al., Cell, 81:107-115 (1995);Josselyn, S. A. et al., J. Neurosci., 21:2404-2412 (2001); Alberini, C.M. et al., Cell, 76:1099-1114 (1994); and Taubenfeld, S. M. et al., J.Neurosci., 21:84-91 (2001)) under control of the CREB transcriptionfactor (Davis, H. P. and Squire, L. R., Psychol. Bull., 96:518-559(1984); Tully, T. et al., Cell, 79:35-47 (1994); Yin, J. C. et al.,Cell, 79:49-58 (1994); Yin, J. C. et al., Cell, 81:107-115 (1995);Josselyn, S. A. et al., J. Neurosci., 21:2404-2412 (2001); Alberini, C.M. et al., Cell, 76:1099-1114 (1994); and Taubenfeld, S. M. et al., J.Neurosci., 21:84-91 (2001)), which leads to structural and functionalchanges in specific synapses (Bartsch, D. et al., Cell, 83:979-992(1995); and Dash, P. K. et al., Nature, 345:718-721 (1990)). LTM isdisrupted by induced over-expression of a CREB repressor transgene inflies (Yin, J. C. et al., Cell, 79:49-58 (1994)), by partial knock-outof CREB in mice (Bourtchuladze, R. et al., Cell, 79:59-68 (1994)), byknock-down of CREB with anti-sense RNA in rats (Guzowski, J. F. andMcGaugh, J. L., Proc. Natl. Acad. Sci. USA, 94:2693-2698 (1997); andLamprecht, R. et al., J. Neurosci., 17:8443-8450 (1997)) or by inducedover expression of a dominant-negative CREB in mice (Kida, S. et al.,Nat. Neurosci., 5:348-355 (2002); and Pittenger, C. et al., Neuron,34:447-462 (2002)). Synaptic plasticity is disrupted similarly inAplysia (Bartsch, D. et al., Cell, 83:979-992 (1995)), in flies (Davis,G. W. et al., Neuron, 17:669-679 (1996); and Sanyal, S. et al., Nature,416:870-874 (2002)) and in mice (Bourtchuladze, R. et al., Cell,79:59-68 (1994); Barco, A. et al., Cell, 108:689-703 (2002); andCasadio, A. et al., Cell, 99:221-237 (1999)). Strikingly, overexpression of CREB activator in transgenic flies, or in virus-infectedrats, enhances LTM (Yin, J. C. et al., Cell, 81:107-115 (1995); andJosselyn, S. A. et al., J. Neurosci., 21:2404-2412 (2001)), whileanalogous modulations of CREB activator enhance (i) long-termfacilitation (LTF) and the concomitant growth of synaptic connections insensorimotor neuron co-cultures of Aplysia (Bartsch, D. et al., Cell,83:979-992 (1995)) and (ii) long-term potentiation (LTP) in rathippocampus (Barco, A. et al., Cell, 108:689-703 (2002)). Theseconvergent data establish that long-term memory (LTM) formation requiresgene transcription (Yin, J. C. et al., Cell, 81:107-115 (1995); Abel, T.et al., Science, 279:338-341 (1998); and Tully, T., Proc. Natl. Acad.Sci. USA, 94:4239-4241 (1997)).

This insight has raised two new questions. First, specifically whatgenes are regulated during LTM formation? Attempts to answer thisquestion have been pursued with in vitro models of neuronal plasticity,with strong pharmacological stimulation in vivo and, in a few cases,with behavioral training (Cole, A. J. et al., Nature, 340:474-476(1989); Hevroni, D. et al., J. Mol. Neurosci., 10:75-98 (1998); Irwin,L. N., Brain Res. Mol. Brain Res., 96:163-169 (2001); Luo, Y. et al., J.Mol. Neurosci., 17:397-404 (2001); Cavallaro, S. et al., Eur. J.Neurosci., 13:1809-1815 (2001); Nedivi, E. et al., Nature, 363:718-722(1993); and Nedivi, E. et al., Proc. Natl. Acad. Sci. USA, 93:2048-2053(1996)). Second, how does a transcriptional response in the cell nucleustag only a subset of synapses involved in LTM (Barco, A. et al., Cell,108:689-703 (2002); Casadio, A. et al., Cell, 99:221-237 (1999); Frey,U. and Morris, R. G., Nature, 385:533-536 (1997); Martin, K. C. et al.,Cell, 91:927-938 (1997); Steward, O. et al., Neuron, 21:741-751 (1998);Steward, O. and Schuman, E. M., Annu. Rev. Neurosci., 24:299-325 (2001);Steward, O. and Worley, P. F., Proc. Natl. Acad. Sci. USA, 98:7062-7068(2001); Steward, O. and Worley, P. F., Neuron, 30:227-240 (2001); andSteward, O. and Worley, P., Results Probl. Cell. Differ., 34:1-26(2001))? Thus far, analyses of in vitro models of synaptic plasticityhave described the cellular phenomenology of synapse specificmodification but have not yet identified the cellular machinery orestablished a connection to memory.

SUMMARY OF THE INVENTION

It has been discovered that STAUFEN plays an important role in mediatingthe cellular events underlying memory formation in mammals. As describedherein, STAUFEN-mediated mRNA trafficking within the hippocampus hasbeen discovered to be important for contextual long-term memoryformation in mammals. It has been discovered that disruption ofhippocampal STAUFEN function impairs long term memory formation inmammals.

The present invention provides cell-based screening methods foridentifying pharmaceutical agents which are capable of modulating (havethe ability to modulate) STAUFEN function by screening for STAUFENfunction. In one embodiment, STAUFEN function is screened by determiningthe level of STAUFEN protein expression (translation). As describedherein, STAUFEN is transcriptionally upregulated during memoryformation. Accordingly, in this embodiment, STAUFEN protein expressioncan be determined by determining STAUFEN mRNA or protein production. Ina second embodiment, STAUFEN function is screened by determining thefunctional readout of STAUFEN. In this embodiment, a functional readoutof STAUFEN can be determined by detecting (such as using an antibody)the translocation of the STAUFEN into dendrites or by determining thelevel of STAUFEN protein production. A functional readout of STAUFEN canalso be determined indirectly by detecting and measuring downstream geneproducts regulated by a staufen gene product. In a third embodiment,STAUFEN function is screened by determining the change in distributionof neural granules in the cells.

By “STAUFEN function” is meant the biological activity of STAUFEN, whichincludes subcellular translocation of various mRNAs and local regulationof various protein translations (“the STAUFEN pathway”). Biologicalactivity is understood to mean biological function or action. By“STAUFEN pathway function” is meant a set of gene products whichinteract with a staufen gene product and/or with each other to produceSTAUFEN function, particularly the subcellular translocation of mRNA andlocal regulation of protein translation.

In a particular embodiment, STAUFEN::indicator fusion protein constructsare employed in cell-based screening methods for identifying apharmaceutical agent which is capable of modulating STAUFEN function.Thus, in one embodiment, a cell-based screening method for identifying apharmaceutical agent which is capable of modulating STAUFEN functioncomprises (a) introducing a pharmaceutical agent of interest into hostcells (particularly cells of neural origin) expressing aSTAUFEN::indicator fusion protein (e.g., STAUFEN::GFP fusion protein);and (b) determining STAUFEN function. In a particular embodiment, thepharmaceutical agent is introduced into cells after stimulation of theCREB pathway using forskolin, for example. By CREB pathway function ismeant CREB-dependent gene expression. The STAUFEN function determined in(b) is compared to the STAUFEN function of the host cells of (a) towhich the pharmaceutical agent has not been introduced (untreated hostcells expressing STAUFEN::indicator fusion protein) (control). Adifference in STAUFEN function determined in the treated cells relativeto the STAUFEN function of untreated cells identifies the pharmaceuticalagent as one which modulates (or is capable of modulating) STAUFENfunction. In one embodiment, STAUFEN function is determined by detectingand determining the level of STAUFEN::indicator fusion proteinexpression (translation) (e.g., by detecting STAUFEN::indicator fusionprotein mRNA or protein production). In a second embodiment, STAUFENfunction is determined by detecting (such as using an antibody) thetranslocation of the STAUFEN::indicator fusion protein into dendrites orby determining the level of STAUFEN::indicator fusion proteinproduction. In a third embodiment, STAUFEN function is determinedindirectly by detecting and measuring downstream gene products regulatedby a staufen gene product. In a fourth embodiment, STAUFEN function isdetermined by determining the change in distribution of neural granulesin the cells.

Pharmaceutical agents which modulate, or are capable of modulating,STAUFEN function are further screened to determine the effect of theagents on long term memory formation or to identify those agents capableof modulating long term memory. In one embodiment, the method comprises(a) administering to an animal (particularly a mammal) a pharmaceuticalagent which modulates, or is capable of modulating, STAUFEN function;(b) training the animal of (a) and a control animal of the same speciesto which the pharmaceutical has not been administered under conditionssufficient to produce long term memory formation in the animals; (c)assessing long term memory formation in the animals trained in step (b);and (d) comparing long term memory formation in the animals assessed instep (c). A control animal is the basis for comparison in assessingresults associated with administration of a pharmaceutical agent to anexperimental animal. The experimental and control animals arecomparable, e.g., same age, genetic makeup, basal STAUFEN function(i.e., STAUFEN function prior to treatment with the pharmaceuticalagent). A difference in long term memory formation assessed in theanimal treated with (administered) the pharmaceutical agent relative tothe long term memory formation assessed in the control animal identifiesthe pharmaceutical agent as one which has the ability to modulate longterm memory formation in the animal.

Pharmaceutical agents which modulate, or are capable of modulating,STAUFEN function are also screened to determine the effect of the agentson performance by an animal of a hippocampal-dependent cognitive task orto identify those agents capable of modulating performance of ahippocampal-dependent cognitive task by an animal. In one embodiment,the method comprises (a) administering to an animal (particularly amammal) a pharmaceutical agent which modulates, or is capable ofmodulating, STAUFEN function; (b) training the animal of (a) and acontrol animal of the same species to which the pharmaceutical agent hasnot been administered under conditions appropriate for performance bythe animals of a specified hippocampal-dependent cognitive task; (c)assessing performance of the hippocampal-dependent cognitive task by theanimals trained in step (b); and (d) comparing performance of theanimals assessed in step (c). The experimental and control animals arecomparable, e.g., same age, genetic makeup, basal STAUFEN function(i.e., STAUFEN function prior to treatment with the pharmaceuticalagent). A difference in assessed performance by the animal treated with(administered) the pharmaceutical agent relative to the assessedperformance by the control animal identifies the pharmaceutical agent asone which has the ability to modulate the performance by the animal ofthe specified hippocampal-dependent cognitive task.

The present invention also provides methods of screening apharmaceutical agent for its ability to modulate long term memoryformation in a mammal, preferably an adult mammal, comprising (a)administering a pharmaceutical agent of interest to a first mammal; (b)determining STAUFEN function in the mammal administered thepharmaceutical agent (a) relative to STAUFEN function in a controlmammal of the same species as the first mammal to which thepharmaceutical agent has not been administered; (c) selecting thepharmaceutical agent if the STAUFEN function determined in (b) differsfrom the STAUFEN function in the control mammal; (d) administering thepharmaceutical agent selected in (c) to a second mammal; (e) trainingthe second mammal administered the pharmaceutical agent (d) and acontrol mammal of the same species as the second mammal under conditionsappropriate to produce long term memory formation in the mammals; (f)assessing long term memory formation in the mammals trained in step (e);and (g) comparing long term memory formation in the mammals assessed instep (f). The first and second mammals can be of the same or differentspecies. The first mammal and the corresponding control mammal arecomparable, e.g., same age, genetic makeup, basal STAUFEN function(i.e., STAUFEN function prior to treatment with the pharmaceuticalagent). Similarly, the second mammal and the corresponding controlmammal are comparable, e.g., same age, genetic makeup, basal STAUFENfunction (i.e., STAUFEN function prior to treatment with thepharmaceutical agent). A difference in long term memory formationassessed in the mammal treated with the pharmaceutical agent relative tothe long term memory formation assessed in the control mammal identifiesthe pharmaceutical agent as one which has the ability to modulate longterm memory formation in the mammal.

The present invention further provides methods of screening apharmaceutical agent for its ability to modulate STAUFEN function in amammal, preferably an adult mammal, comprising (a) administering apharmaceutical agent of interest to a mammal; and (b) determiningSTAUFEN function in the mammal administered the pharmaceutical agent (a)relative to STAUFEN function in a control mammal of the same species towhich the pharmaceutical agent has not been administered. Theexperimental and control mammals are comparable, e.g., same age, geneticmakeup, basal STAUFEN function (i.e., STAUFEN function prior totreatment with pharmaceutical agent). A difference in STAUFEN functiondetermined in the mammal treated with the pharmaceutical agent relativeto STAUFEN function determined in the control mammal identifies thepharmaceutical agent as one having the ability to modulate STAUFENfunction in the mammal.

The invention further relates to methods for assessing the effect of apharmaceutical agent on long term memory formation in a mammal,preferably an adult mammal, comprising (a) administering apharmaceutical agent of interest to a first mammal; (b) determiningSTAUFEN function in the mammal administered the pharmaceutical agent (a)relative to STAUFEN function in a control mammal of the same species asthe first mammal to which the pharmaceutical agent has not beenadministered; (c) selecting the pharmaceutical agent if the STAUFENfunction determined in (b) differs from the STAUFEN function in thecontrol mammal; (d) administering the pharmaceutical agent selected in(c) to a second mammal; (e) training the second mammal administered thepharmaceutical agent in (d) a control mammal of the same species as thesecond mammal under conditions appropriate to produce long term memoryformation in the mammals; (f) assessing long term memory formation inthe mammals trained in step (e); and (g) comparing long term memoryformation in the mammals assessed in step (f). The first and secondmammals can be of the same or different species. The first mammal andthe corresponding control mammal are comparable, e.g., same age, geneticmakeup, basal STAUFEN function (i.e., STAUFEN function prior totreatment with the pharmaceutical agent). Similarly, the second mammaland the corresponding control mammal are comparable, e.g., same age,genetic makeup, basal STAUFEN function (i.e., STAUFEN function prior totreatment with the pharmaceutical agent). A difference in long termmemory formation assessed in the mammal treated with the pharmaceuticalagent relative to the long term memory formation assessed in the controlmammal identifies the pharmaceutical agent as one having an effect onlong term memory formation in the mammal.

The invention also relates to methods of assessing the effect of apharmaceutical agent on STAUFEN function in a mammal, preferably anadult mammal, comprising (a) administering a pharmaceutical agent ofinterest to the mammal; and (b) determining STAUFEN function in themammal administered the pharmaceutical agent in (a) relative to STAUFENfunction in a control mammal of the same species to which thepharmaceutical agent has not been administered. The experimental andcontrol mammals are comparable, e.g., same age, genetic makeup, basalSTAUFEN function (i.e., STAUFEN function prior to treatment withpharmaceutical agent). A difference in STAUFEN function determined inthe mammal treated with the pharmaceutical agent relative to STAUFENfunction determined in the control mammal identifies the pharmaceuticalagent as one having an effect on STAUFEN function in the mammal.

The invention also relates to methods of screening a pharmaceuticalagent for its ability to modulate performance of a hippocampal-dependentcognitive task by a mammal, preferably an adult mammal, comprising (a)administering a pharmaceutical agent of interest to a first mammal; (b)determining STAUFEN function in the mammal administered thepharmaceutical agent (a) relative to STAUFEN function in a controlmammal of the same species as the first mammal to which thepharmaceutical agent has not been administered; (c) selecting thepharmaceutical agent if STAUFEN function determined in (b) differs fromthe STAUFEN function in the control mammal; (d) administering thepharmaceutical agent selected in (c) to a second mammal; (e) trainingthe mammal administered the pharmaceutical agent in (d) and a controlmammal of the same species as the second mammal under conditionsappropriate for performance by the mammals of a specifiedhippocampal-dependent cognitive task; (f) assessing performance of thehippocampal-dependent cognitive task by the mammals trained in step (e);and (g) comparing performance of the hippocampal-dependent cognitivetask by the mammals assessed in step (f). The first and second mammalscan be of the same or different species. The first mammal and thecorresponding control mammal are comparable, e.g., same age, geneticmakeup, basal STAUFEN function (i.e., STAUFEN function prior totreatment with the pharmaceutical agent). Similarly, the second mammaland the corresponding control mammal are comparable, e.g., same age,genetic makeup, basal STAUFEN function (i.e., STAUFEN function prior totreatment with the pharmaceutical agent). A difference in assessedperformance by the mammal treated with the pharmaceutical agent relativeto the assessed performance by the control mammal identifies thepharmaceutical agent as one which has the ability to modulate theperformance by the mammal of the specified hippocampal-dependentcognitive task.

The invention further relates to methods for assessing the effect of apharmaceutical agent on performance of a hippocampal-dependent cognitivetask by a mammal, preferably an adult mammal, comprising (a)administering a pharmaceutical agent of interest to a first mammal; (b)determining STAUFEN function in the mammal administered thepharmaceutical agent in (a) relative to STAUFEN function in a controlmammal of the same species as the first mammal to which thepharmaceutical agent has not been administered; (c) selecting thepharmaceutical agent if the STAUFEN function determined in (b) differsfrom the STAUFEN function in the control mammal; (d) administering thepharmaceutical agent selected in (c) to a second mammal; (e) trainingthe mammal administered the pharmaceutical agent in step (d) and acontrol mammal of the same species as the second mammal under conditionsappropriate for performance by the mammals of a specifiedhippocampal-dependent cognitive task; (f) assessing performance of thehippocampal-dependent cognitive task by the mammals trained in step (e);and (g) comparing the performance of the hippocampal-dependent cognitivetask by the mammals assessed in step (f). The first and second mammalscan be of the same or different species. The first mammal and thecorresponding control mammal are comparable, e.g., same age, geneticmakeup, basal STAUFEN function (i.e., STAUFEN function prior totreatment with the pharmaceutical agent). Similarly, the second mammaland the corresponding control mammal are comparable, e.g., same age,genetic makeup, basal STAUFEN function (i.e., STAUFEN function prior totreatment with the pharmaceutical agent). A difference in assessedperformance by in the mammal treated with the pharmaceutical agentrelative to the assessed performance by the control mammal identifiesthe pharmaceutical agent as one having an effect on performance by themammal of the specified hippocampal-dependent cognitive task.

Training can comprise one or multiple training sessions and is trainingappropriate for long term memory formation or for performance of thespecified cognitive task. The pharmaceutical agent can be administeredbefore, during or after one or more training sessions.

The invention also provides methods for modulating long term memoryformation in a mammal. In a particular embodiment, the mammal is anadult mammal. In one embodiment, the method comprises treating themammal to modulate staufen-dependent protein expression. In a secondembodiment, the method comprises treating the mammal to modulate STAUFENfunction. In a particular embodiment, the method comprises administeringto the mammal an effective amount of a pharmaceutical agent whichmodulates STAUFEN function in the mammal. In another embodiment, themethod comprises treating the mammal to modulate STAUFEN proteinexpression. In a particular embodiment, the method comprisesadministering to the mammal an effective amount of a pharmaceuticalagent which modulates STAUFEN protein expression in the mammal.

The present invention also provides methods for enhancing long termmemory formation in a mammal. In a particular embodiment, the mammal isan adult mammal. In one embodiment, the method comprises treating themammal to modulate staufen-dependent protein expression. In a secondembodiment, the method comprises treating the mammal to increase STAUFENfunction relative to the STAUFEN function in the mammal prior totreatment. In a particular embodiment, treatment to increase STAUFENfunction comprises administering to the mammal an effective amount of apharmaceutical agent which increases STAUFEN function relative toSTAUFEN function in the mammal prior to administration of thepharmaceutical agent. In another embodiment, the method comprisestreating the mammal to increase STAUFEN protein expression relative toSTAUFEN protein expression in the mammal prior to treatment. In aparticular embodiment, treatment to increase STAUFEN protein expressioncomprises administering to the mammal an effective amount of apharmaceutical agent which increases STAUFEN protein expression relativeto STAUFEN protein expression in the mammal prior to administration ofthe pharmaceutical agent. In still another embodiment, the methodcomprises administering to the mammal an effective amount of exogenousSTAUFEN, STAUFEN analog, biologically active STAUFEN fragment or STAUFENfusion protein. In yet another embodiment, the method comprisesadministering to the mammal an effective amount of a nucleic acidsequence encoding exogenous STAUFEN, STAUFEN analog, biologically activeSTAUFEN fragment or STAUFEN fusion protein.

The present invention further provides methods for treating a mammalwith a defect in long term memory formation associated with a defect inSTAUFEN. The mammal is preferably an adult mammal. The defect in STAUFENis either a diminution in the amount of STAUFEN produced, a diminutionin STAUFEN function of STAUFEN produced or both a diminution in amountof STAUFEN produced and STAUFEN function of STAUFEN produced. In oneembodiment, the method comprises treating a mammal with a defect in longterm memory formation associated with a defect in STAUFEN to increaseSTAUFEN function relative to the STAUFEN function in the mammal prior totreatment. In a particular embodiment, treatment to increase STAUFENfunction comprises administering to the mammal an effective amount of apharmaceutical agent which increases STAUFEN function relative toSTAUFEN function in the mammal prior to administration of thepharmaceutical agent. In a second embodiment, the method comprisestreating a mammal with a defect in long term memory formation associatedwith a defect in STAUFEN to increase STAUFEN protein expression relativeto STAUFEN protein expression in the mammal prior to treatment. In aparticular embodiment, treatment to increase STAUFEN protein expressioncomprises administering to the mammal an effective amount of apharmaceutical agent which increases STAUFEN protein expression relativeto STAUFEN protein expression in the mammal prior to administration ofthe pharmaceutical agent. In a another embodiment, the method comprisesadministering to a mammal with a defect in long term memory formationassociated with a defect in STAUFEN, a STAUFEN compound such asexogenous STAUFEN, STAUFEN analog, biologically active STAUFEN fragmentor STAUFEN fusion protein. In still another embodiment, the methodcomprises administering to a mammal with a defect in long term memoryformation with a defect in STAUFEN, a nucleic acid sequence encodingexogenous STAUFEN, STAUFEN analog, biologically active STAUFEN fragmentor STAUFEN fusion protein.

The invention also provides methods for modulating performance of ahippocampal-dependent cognitive task by a mammal. In a particularembodiment, the mammal is an adult mammal. In one embodiment, the methodcomprises treating the mammal to modulate staufen-dependent proteinexpression. In a second embodiment, the method comprises treating themammal to modulate STAUFEN function. In a particular embodiment, themethod comprises administering to the mammal an effective amount of apharmaceutical agent which modulates STAUFEN function in the mammal. Inanother embodiment, the method comprises treating the mammal to modulateSTAUFEN protein expression. In a particular embodiment, the methodcomprises administering to the mammal an effective amount of apharmaceutical agent which modulates STAUFEN protein expression in themammal.

The present invention provides methods for enhancing performance of ahippocampal-dependent cognitive task by a mammal. The mammal ispreferably an adult mammal. In one embodiment, the method comprisestreating the mammal to modulate staufen-dependent protein expression. Ina second embodiment, the method comprises treating the mammal toincrease STAUFEN function relative to STAUFEN function in the mammalprior to treatment. In a particular embodiment, treatment to increaseSTAUFEN function comprises administering to the mammal an effectiveamount of a pharmaceutical agent which increases STAUFEN functionrelative to STAUFEN function in the mammal prior to administration ofthe pharmaceutical agent. In another embodiment, the method comprisestreating the mammal to increase STAUFEN protein expression relative toSTAUFEN protein expression in the mammal prior to treatment. In aparticular embodiment, treatment to increase STAUFEN protein expressioncomprises administering to the mammal an effective amount of apharmaceutical agent which increases STAUFEN protein expression relativeto STAUFEN protein expression in the mammal prior to administration ofthe pharmaceutical agent. In another embodiment, the method comprisesadministering to the mammal an effective amount of exogenous STAUFEN,STAUFEN analog, biologically active STAUFEN fragment or STAUFEN fusionprotein. In still another embodiment, the method comprises administeringto the mammal an effective amount of a nucleic acid sequence encodingexogenous STAUFEN, STAUFEN analog, biologically active STAUFEN fragmentor STAUFEN fusion protein.

The present invention further provides methods for treating a mammalwith a defect in performance of a hippocampal-dependent cognitive task,wherein the defect in performance is associated with a defect inSTAUFEN. The mammal is preferably an adult mammal. The defect in STAUFENis either a diminution in the amount of STAUFEN produced, a diminutionin STAUFEN function of STAUFEN produced or both a diminution in amountof STAUFEN produced and STAUFEN function of STAUFEN produced. In oneembodiment, the method comprises treating a mammal with a defect inperformance of a hippocampal-dependent cognitive task associated with adefect in STAUFEN to increase STAUFEN function relative to STAUFENfunction in the mammal prior to treatment. In a particular embodiment,treatment to increase STAUFEN function comprises administering to themammal an effective amount of a pharmaceutical agent which increasesSTAUFEN function relative to STAUFEN function in the mammal prior toadministration of the pharmaceutical agent. In a second embodiment, themethod comprises treating a mammal with a defect in performance of ahippocampal-dependent cognitive task associated with a defect in STAUFENto increase STAUFEN protein expression relative to STAUFEN proteinexpression in the mammal prior to treatment. In a particular embodiment,treatment to increase STAUFEN protein expression comprises administeringto the mammal an effective amount of a pharmaceutical agent whichincreases STAUFEN protein expression relative to STAUFEN proteinexpression in the mammal prior to administration of the pharmaceuticalagent. In another embodiment, the method comprises administering to amammal with a defect in performance of a hippocampal-dependent cognitivetask associated with a defect in STAUFEN, a STAUFEN compound such asexogenous STAUFEN, STAUFEN analog, biologically active STAUFEN fragmentor STAUFEN fusion protein. In still another embodiment, the methodcomprises administering to a mammal with a defect in performance of ahippocampal-dependent cognitive task associated with a defect inSTAUFEN, a nucleic acid sequence encoding exogenous STAUFEN, STAUFENanalog, biologically active STAUFEN fragment or STAUFEN fusion protein.

The invention also provides methods for modulating performance by amammal of cognitive tasks associated with non-hippocampal regions of thebrain where staufen gene expression is found to occur, methods fortreating a defect in performance by an animal of cognitive tasksassociated with non-hippocampal regions of the brain where staufen geneexpression is found to occur and methods for screening a pharmaceuticalagent for its ability to modulate performance by an animal of cognitivetasks associated with non-hippocampal regions of the brain where staufengene expression is found to occur. Such methods are similar to themethods described herein for modulating performance by a mammal ofhippocampal-dependent cognitive tasks, for treating a defect inperformance by an animal of hippocampal-dependent cognitive tasks andfor screening a pharmaceutical agent for its ability to modulateperformance by an animal of hippocampal-dependent cognitive tasks.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a bar graph representation of the effect on memory in micefour days after training in a contextual fear conditioning task. Micewere trained with 1, 2, 5 or 10 training trials (1×, 2×, 5× and 10×; 0.5mA shock for 2 seconds; n=22, n=20, n=19 and n=22 animals,respectively). 5× yields maximal levels of long-term memory, which isnot significantly different from memory induced by 10× (P>0.05). 2×yields less than half maximal levels (P<0.001 for 2× vs. 5×).

FIG. 2 is a bar graph representation of the effect of CREBoligodeoxynucleotides (ODNs) treatment on memory in mice after training.CREB ODNs decreased memory induced by strong training (5 trials) to thelevels produced by weak training (2 trials). CREB ODNs or scrambled CREBwere delivered into the hippocampus (2 nmol/2 μl) 20 hours beforetraining mice with weak (2 trials) or strong training (5 trials). Micewere tested 4 days after training. CREB ODNs significantly impairedmemory induced by strong training (p<0.01; n=17 and n=14 for CREB ODNs-and scrambled CREB-injected animals, respectively) but had no effect onthe memory levels produced by weak training (p=0.47; n=12 and n=11 forCREB ODNs- and scrambled CREB-injected animals, respectively).

FIG. 3 is a bar graph representation of the effect of Rolipram treatmenton memory in mice after weak training in a contextual fear conditioningtask. Memory is enhanced in C57B16 mice by Rolipram after weak trainingin a contextual fear conditioning task. Rolipram or vehicle weredelivered into the hippocampus (30 ng/1 μl per hippocampus) immediatelyafter training mice with weak (2 trials) or strong training (5 trials).Mice were tested 4 days after training. Rolipram significantly enhancedmemory induced by weak training (p<0.001; n=12 and n=24 for Rolipram andvehicle injected animals, respectively) but had no effect on the maximalmemory levels produced by strong training (p=0.93; n=8 and n=13 for drugand vehicle injected animals, respectively). Similarly, injection of 3ng Rolipram produced memory enhancing effect on weak training (p<0.005;n=16). However, 0.03 ng Rolipram had no memory enhancing effect (p<0.42;n=8).

FIG. 4 is a bar graph representation of the effect of anisomycin (ANI)treatment on memory in mice after training. Contextual conditioningmemory is anisomycin sensitive. ANI (62.5 mg/2 μl per hippocampus) orvehicle was delivered into the hippocampus immediately after training.Mice were tested 4 days after training. ANI significantly impairedmemory induced strong (p<0.01; n=13 and n=11 for ANI- andvehicle-injected mice, respectively) or weak training (p<0.05; n=10 andn=12 for ANI- and vehicle-injected mice, respectively).

FIG. 5 is a bar graph representation of the effect of staufen ODNstreatment on memory in mice after training. Staufen ODNs impair 4-daymemory in mice. Staufen ODNs or scrambled staufen were delivered intothe hippocampus (4 nmol/2 ml per hippocampus, 44 hours and 15 hoursbefore training, and immediately after training. Staufen ODNssignificantly impaired memory induced by strong training (p<0.05; n=12and n=10 for staufen ODNs and scrambled staufen-injected animals,respectively) but had no significant effect on the memory produced byweak training (p=0.08; n=7 and n=10 for staufen ODNs and scrambledstaufen-injected animals, respectively).

FIG. 6 is a bar graph representation showing 24 hour memory inDrosophila after spaced training in wildtype controls andtemperature-sensitive staufen mutants. Memory was assessed using aPavlovian assay (Tully, T. et al., Cell, 79:35-47 (1994); and Tully, T.and Quinn, W. G., J. Comp. Physiol. [A], 157:263-277 (1985)) in which anodor (CS) is paired with a footshock (US). One-day memory after spacedtraining is equivalent in wildtype controls and temperature-sensitivestaufen (stau^(C8)/stau^(D3)) mutants when animals were trained, storedduring the 24 hour retention interval, and tested at the permissivetemperature (P=0.44 (18° C.)). In contrast, one-day memory after spacedtraining was disrupted specifically in stau mutants (P<0.001) when theywere trained and tested at permissive temperature but were shifted torestrictive temperature (29° C.) during the retention interval. N=16 PIsper group.

FIGS. 7A and 7B are schematic diagrams depicting a model describedherein for synapse-specific modification underlying long-term memory.

FIG. 7A shows that transcripts induced by spaced training are packagedinto neural granules (GR) along with other functional componentsincluding stau, osk, faf and mago, which are required to translocate GRalong microtubules (MT) into neuronal processes dendrites (Krichevsky,A. M. and Kosik, K. S., Neuron, 32:683-696 (2001); Kiebler, M. A. etal., J. Neurosci., 19:288-297 (1999); and Kohrmann, M. et al., Mol.Biol. Cell., 10: 2945-2953 (1999)). Disassembly of GR and derepressionof packaged mRNAs occur in response to depolarization (Krichevsky, A. M.and Kosik, K. S., Neuron, 32:683-696 (2001)).

FIG. 7B shows detail of the boxed area from FIG. 7A. mRNAs packaged intoGR are translationally repressed by RNA binding proteins, including PUM,NOS, MASKIN and (inactive) ORB. Synaptic depolarization stimulates localkinases, such as aurora kinase, cdc2-kinase (and perhaps others) tophosphorylate ORB. Activated ORB promotes elongation of polyA tail (Wu,L. et al., Neuron, 21:1129-1139 (1998)) and induces the release of eIF4Efrom MASKIN (Stebbins-Boaz, B. et al., Mol. Cell., 4:1017-1027 (1999)).eIF4E then is free to associate with the rest of the translationinitiation complex. OSKAR, 5C and CYC B were identified in a DNA chipscreen. CREB, STAU, FAF, MAGO, PUM, ORB and CDC2 were identified from anindependent behavioral screen for memory mutants.

DETAILED DESCRIPTION OF THE INVENTION

In various species, long-term memory (LTM) is defined by two mainbiological properties. First, formation of long-term memory requiressynthesis of new proteins. Second, it involves cAMP-responsivetranscription and is mediated through the cAMP-response element bindingprotein (CREB) family transcription factors. Thus, numerous earlystudies demonstrated that infusions of protein synthesis inhibitors andRNA synthesis inhibitors around the time of training, blocks long-termmemory but not short-term memory. A compelling role for CREB as amolecular switch for long-term memory emerged from an analysis of recent“loss- and gain-of-function” experiments in Drosophila, Aplysia, miceand rats. Specifically, blocking CREB function has no effect on initiallearning or early memory, but long-term memory does not form. EnhancingCREB function causes long term memory to form with less training(practice)—the functional equivalent of a photographic memory.

In vertebrates, CREB is expressed widely in the brain and appearsinvolved in various aspects of developmental and behavioral plasticity(both implicit and explicit forms of memory). These observationssuggest, more generally, that pharmacological enhancers of the CREBpathway will reduce the requirement for repetitive “training sessions”to achieve performance gains from cognitive training, while inhibitionof CREB pathway, will reduce memory.

Based on cellular studies of CREB function in neurons, a “weak versusstrong” contextual fear conditioning protocol was developed that wouldbe sensitive to “upstream” modulation of the CREB pathway (Kaang, B. K.et al., Neuron, 10(3):427-435 (1993)). During acquisition, repeatedtraining trials lead to increases in cAMP levels and activation ofprotein kinase A (PKA). After surpassing a threshold level, activatedPKA (catalytic subunit) is translocated to the nucleus, where itphosphorylates CREB (or it yields a permissive state for thephosphorylation of CREB by a cofactor). Phosphorylated CREB induces thetranscription of genes encoding proteins required for long-lastingplasticity and memory. In this context:

-   -   i) Phosphodiesterase inhibitors (PDEI) would act to increase        cAMP levels beyond the threshold in fewer training trials,        thereby producing optimal long-term memory with “weaker” (less)        training.    -   ii) Disruption of CREB expression would reduce long-tem memory        induced by “strong” training to the levels produced by “weak”        training.    -   iii) Long-term memory for contextual fear conditioning would be        sensitive to inhibitors of protein synthesis administered around        the time of training.    -   iv) Neuronal genes working in “orchestrated” manner with CREB        pathway would be involved in learning and/or memory.

Contextual fear conditioning is a form of associative learning in whichanimals learn to recognize a training environment (conditioned stimulus,CS) that has been previously paired with an aversive stimulus such asfoot shock (unconditioned stimulus, US). When exposed to the samecontext at a later time, conditioned animals show a variety ofconditional fear responses, including freezing behavior (Fanselow, M.S., Behav. Neurosci., 98:269-277 (1984); Fanselow, M. S., Behav.Neurosci., 98:79-95 (1984); and Phillips, R. G. and LeDoux, J. E.,Behav. Neurosci., 106:274-285 (1992)). Contextual conditioning has beenused to investigate the neural substrates mediating fear-motivatedlearning (Phillips, R. G. and LeDoux, J. E., Behav. Neurosci.,106:274-285 (1992); and Kim, J. J. et al., Behav. Neurosci.,107:1093-1098 (1993)). Recent studies in mice and rats provided evidencefor functional interaction between hippocampal and nonhippocampalsystems during contextual conditioning training (Maren, S. et al.,Behav. Brain Res., 88(2):261-274 (1997); Maren, S. et al., Neurobiol.Learn. Mem., 67(2):142-149 (1997); and Frankland, P. W. et al., Behav.Neurosci., 112:863-874 (1998)). Specifically, post-training lesions ofthe hippocampus (but not pre-training lesions) greatly reducedcontextual fear, implying that: 1) the hippocampus is essential forcontextual memory but not for contextual learning per se and 2) in theabsence of the hippocampus during training, non-hippocampal systems cansupport contextual conditioning.

Contextual conditioning has been extensively used to study the impact ofvarious mutations on hippocampus-dependent learning and memory(Bourtchouladze et al., Cell, 79:59-68 (1994); Bourtchouladze et al.,Learn Mem., 5(4-5):365-374 (1998); Kogan, J. H. et al., Current Biology,7(1):1-11 (1997); Silva A. J. et al., Current Biology, 6(11):1509-1518(1996); Abel, T. et al., Cell, 88:615-626 (1997); and Giese, K. P. etal., Science, 279:870-873 (1998)) and strain differences in mice (Logue,S. F. et al., Neuroscience, 80(4):1075-1086 (1997); Chen, C. et al.,Behav. Neurosci., 110:1177-1180 (1996); and Nguyen, P. V. et al., LearnMem., 7(3):170-179 (2000)). Because robust learning can be triggeredwith a few minutes training session, contextual conditioning has beenespecially useful to study the biology of temporally distinct processesof short- and long-term memory (Kim, J. J. et al., Behav. Neurosci.,107:1093-1098 (1993); Abel, T. et al., Cell, 88:615-626 (1997);Bourtchouladze et al., Cell, 79:59-68 (1994); Bourtchouladze et al.,Learn Mem., 5(4-5):365-374 (1998)). As such, contextual conditioningprovides an excellent model to evaluate the role of various novel genesin hippocampal-dependent memory formation.

One such gene is a gene encoding a STAUFEN protein. STAUFEN is acritical protein for the targeting of specific mRNAs in Drosophiladuring development (Li, P. et al., Cell, 90:437-447 (1997); andEphrussi, A. and Lehmann, R., Nature, 358:387-392 (1992)). Recently, itwas shown to be present in the adult rat brain as well. Specifically,STAUFEN was detected in somata and dendrites of neurons of the adult rathippocampus and cerebral cortex (Monshausenm M. et al., J. Neurochem.,76:155-165 (2001)). In hippocampal neurons, STAUFEN accumulates alongmicrotubules and is thought to participate in the trafficking of mRNA(Tang, S. J. et al., Neuron, 32(3):463-475 (2001)).

Recent studies in Drosophila identified STAUFEN as a candidate memorygene (CMG) expressed at a high level after long term memory formation.Moreover, temporary disruption of STAUFEN function intemperature-sensitive stau^(C8)/stau^(D3) mutant flies, almostcompletely abolished 24 hour memory, indicating an acute requirement forSTAUFEN during memory consolidation.

Applicants have discovered that STAUFEN plays an important role inmediating the cellular events underlying memory formation in mammals. Asdescribed herein, to examine the functional connection of hippocampalSTAUFEN to contextual long-term memory formation, hippocampal infusionsof antisense oligonucleotides (ODNs) directed against Staufen mRNA wereperformed. To validate the sensitivity of a “weak versus strong”training-induced memory on CREB-dependent transcription and proteinsynthesis, a combined behavioral, pharmacological and ODN approach wasused.

Five training trials (5× “strong” training) was found to induce maximallevels of long term contextual memory, which is significantly strongerthan memory induced by two training trials (2×, “weak” training). Byinjecting the CREB antisense oligonucleotides into the hippocampusbefore training, a reduction of memory induced by strong training to thelevels produced by weak training was observed. Similarly, injection ofstaufen antisense oligonucleotides into the hippocampus reduced memoryinduced by strong training. In contrast, Rolipram, a type-IVphosphodiesterase inhibitor, administered immediately after training,enhances the amount of memory induced by weak training to the levelsproduced by strong training. Finally, an inhibitor of protein synthesis,anisomycin (ANI), blocks both weak- and strong training-inducedcontextual memory.

Combined, these studies underscore the parallel dependence of long-termcontextual memory induced by strong training on protein synthesis andCREB-dependent transcription and they implicate the involvement ofhippocampal STAUFEN in contextual memory formation.

mRNAs are present in neuronal dendrites and may be used for localprotein synthesis in response to synaptic activity (Steward, O. andLevy, W. B., J. Neurosci., 2:284-291 (1982); and Schuman, E. M., Neuron,23:645-648 (1999)). Recent studies have demonstrated that dendriticprotein synthesis can accompany plasticity and participate inlong-lasting synaptic changes (Wu, L. et al., Neuron, 21:1129-1139(1998); Huber, K. M. et al., Science, 288:1254-1257 (2000); and Casadio,A. et al., Cell, 99:221-237 (1999)).

STAUFEN already has been implicated in mRNA localization in mammalianneurons. In hippocampal neurons, STAUFEN has a punctate,somato-dendritic distribution and is a component of large RNP-containingneural granules, which themselves are associated with microtubules(Steward, O. and Schuman, E. M., Annu. Rev. Neurosci., 24:299-325(2001); Krichevsky, A. M. and Kosik, K. S., Neuron, 32:683-696 (2001);Tang, S. J. et al., Neuron, 32:463-475 (2001); Kiebler, M. A. et al., J.Neurosci., 19:288-297 (1999); Kohrmann, M. et al., Mol. Biol. Cell., 10:2945-2953 (1999); and Aakalu, G. et al., Neuron, 30:489-502 (2001)).These neural granules appear to play an analogous role in targeting mRNAtranslation to subcellular (synaptic) compartments in neurons, as dopolar granules in Drosophila oocytes (Steward, O. and Schuman, E. M.,Annu. Rev. Neurosci., 24:299-325 (2001); Johnstone, O. and Lasko, P.,Annu. Rev. Genet., 35:365-406 (2001); Palacios, I. M. and Johnston, D.S., Annu. Rev. Cell. Dev. Biol., 17:569-614 (2001); Tang, S. J. et al.,Proc. Natl. Acad. Sci. USA, 99:467-472 (2002); Aakalu, G. et al.,Neuron, 30:489-502 (2001); Crino, P. B. and Eberwine, J., Neuron,17:1173-1187 (1996); and Torre, E. R. and Steward, O., J. Neurosci.,12:762-772 (1992)). In cultured hippocampal neurons, neural granules arelocated near dendritic spines and appear to dissociate in response tolocal synaptic activity, thereby releasing translationally repressedmRNAs. This process has been proposed as a mechanism forsynapse-specific modification via local protein synthesis in response toneural activity (Steward, O. and Schuman, E. M., Annu. Rev. Neurosci.,24:299-325 (2001)). The occurrence in dendrites of protein synthesis andthe presence there of the cellular machinery for translation are firmlyestablished (Tang, S. J. et al., Proc. Natl. Acad. Sci. USA, 99:467-472(2002); Aakalu, G. et al., Neuron, 30:489-502 (2001); Crino, P. B. andEberwine, J., Neuron, 17:1173-1187 (1996); and Torre, E. R. and Steward,O., J. Neurosci., 12:762-772 (1992)). The findings described hereinimply that these cellular processes are engaged during long term memoryformation and, more generally, that the similarity between polargranules in the oocyte and neural granules in neurons is not limited toSTAUFEN protein. Thus, the mechanistic relations among many CMGs likelywill be similar in neurons as occur for trafficked genes in oocytes. Byanalogy to what is known about local translational control in embryos,it is reasonable to expect that additional components of neural granulesthat are suggested as CMGs from DNA chip experiments or as memorymutants from complementary behavioral experiments also will be involvedin this neuronal process underlying long-term memory formation.

DNA chip experiments on wildtype Drosophila and behavioral screens formemory mutants in Drosophila have identified fat facets (faf), magonashi (mago), pumilio (pum), orb, cdc2, eIF2G, eIF-5C, oskar (osk) andcyclin B as CMGs, which are known to interact with staufen (stau). Thestaufen, fat facets, mago nashi, pumilio, orb, cdc2 and eIF2G genes wereidentified directly from the DNA chip experiments as transcriptionallyregulated genes during long term memory formation. The eIF-5C, oskar andcyclin B genes were identified from the behavioral screens for memorymutants (defective in one-day memory after spaced training). Together,these genetic components, staufen (FlyBase #FBgn0003520; vertebratehomologs: gi:4759176 (human), gi:4335945 (mouse)), fat facets (FlyBase#FBgn0005632; vertebrate homologs: gi:4759294 (human), MGI:89468(mouse)), mago nashi (FlyBase #FBgn0002736; vertebrate homolog:gi:4505087 (human)), pumilio (FlyBase #CG1755; FlyBase #FBgn0003165;vertebrate homolog: gi:1944416 (human)), orb (FlyBase #FBgn0004882;vertebrate homologs: gi:4589524 (human), MGI:108442 (mouse)), cdc2(FlyBase #FBgn0004106; vertebrate homologs: gi:4502709 (human),MGI:88351 (mouse)), eIF2G (FlyBase #FBgn0003600; vertebrate homologs:gi:4503507 (human), gi:3790184 (mouse)), eIF-5C (FlyBase #CG2922;vertebrate homologs: gi:286001 (human), gi: 4426565 (rat)), oskar(FlyBase #CG10901) and cyclin B (FlyBase #CG3510; vertebrate homologs:OMIM:123836 (human), MGI:88298 (mouse)) (Gelbart, W. M., et al., NucleicAcids Research, 25:63-66 (1997); Flybase,http://flybase.bio.indiana.edu/, Nucleic Acids Research, 27:85-88(1999)), define a biological pathway involved with subcellularlocalization of mRNAs and local regulation of translation, a cellularmechanism that may link CREB-dependent transcription in the nucleus withthe tagging of specific synapses underlying long-term memory formation.This pathway is also referred to herein as the “staufen pathway”, the“pumilio pathway” or the “pumilio/staufen pathway”. The evolutionaryconservation of gene function that has been observed repeatedlyindicates that many homologs of identified Drosophila genes likelysubserve similar roles in vertebrate memory formation.

A model for synapse-specific modification underlying long-term memoryformation is shown in FIGS. 7A-7B. First, behavioral training results inactivation of CREB-mediated transcription and nascent mRNAs are packagedinto an RNP complex, a neural granule. These granules likely includegenetic components of polar granules such as stau, osk, mago and faf andperhaps additional RNA binding CMGs (RNP-4f, hnRNP-A1, no-on transientA, PO, GCR101, La). These neural granules then are transported intodendritic shafts along an organized microtubule network (Johnstone, O.and Lasko, P., Annu. Rev. Genet., 35:365-406 (2001); Palacios, I. M. andJohnston, D. S., Annu. Rev. Cell. Dev. Biol., 17:569-614 (2001); Tang,S. J. et al., Neuron, 32:463-475 (2001); and Kohrmann, M. et al., Mol.Biol. Cell., 10: 2945-2953 (1999)). Activity-induced transcripts may bedelivered to all dendrites or selectively to sites of recent synapticactivity (Barco, A. et al., Cell, 108:689-703 (2002); Frey, U. andMorris, R. G., Nature, 385:533-536 (1997); Martin, K. C. et al., Cell,91:927-938 (1997); and Steward, O. and Worley, P. F., Neuron, 30:227-240(2001)). In either case, packaged mRNAs likely are translationallyquiescent while in transport (Krichevsky, A. M. and Kosik, K. S.,Neuron, 32:683-696 (2001)), thereby preventing ubiquitous expression. Itis reasonable to expect that this translational repression complexincludes pum. In this model, synapse-specific modification results fromthe depolarization-dependent release of neural granule-associated mRNAsand translational derepression at recently active synapses (Krichevsky,A. M. and Kosik, K. S., Neuron, 32:683-696 (2001); and Aakalu, G. etal., Neuron, 30:489-502 (2001)).

The process of derepression appears to involve phosphorylation of CPEB(orb) by aurora kinase, resulting in cytoplasmic polyadenylation(Richter, J. D., Proc. Natl. Acad. Sci. USA, 98:7069-7071 (2001); Wells,D. G. et al., Curr. Opin. Neurobiol., 10:132-137 (2000); Wu, L. et al.,Neuron, 21:1129-1139 (1998); and Huang, Y. S. et al., EMBO J.,21:2139-2148 (2002)) and the dissociation of MASKIN from eIF4-E, whichthen allows interaction between eIF4-E with eIF4-G (Stebbins-Boaz, B. etal., Mol. Cell., 4:1017-1027 (1999)). Release of eIF-4E viaphosphorylation of other 4E binding proteins also may promote assemblyof the rest of the translation initiation complex (Tang, S. J. et al.,Proc. Natl. Acad. Sci. USA, 99:467-472 (2002)). The presence duringsynaptic or behavioral plasticity of several persistently active kinasesalso may contribute to such phosphorylation (Tang, S. J. et al., Proc.Natl. Acad. Sci. USA, 99:467-472 (2002); Ling, D. S. et al., Nat.Neurosci., 5:295-296 (2002); Drier, E. A. et al., Nat. Neurosci.,5:316-324 (2002); Selcher, J. C. et al., Neuroscientist, 8:122-131(2002); Chain, D. G. et al., J. Neurosci., 15:7592-7603 (1995); andMuller, U. and Carew, T. J., Neuron, 21:1423-1434 (1998)). Finally,CPEB-mediated translational activation in Xenopus oocytes is associatedwith phosphorylation of ORB by CDC2 kinase (which is a dimer of CycB andCDC2) (Mendez, R. et al., EMBO J., 21:1833-1844 (2002)) andubiquitin-mediated degradation of ORB (Reverte, C. G. et al., Dev.Biol., 231:447-458 (2001)), perhaps modulated by faf. The DNA chip andmemory mutant experiments have identified several potential components(pum, orb, cdc2, CycB, faf, eIF5-C, eIF2-G, and ribosomal protein PO).

The results link two biological phenomena of LTM, transcriptiondependence and synaptic tagging (Barco, A. et al., Cell, 108:689-703(2002); Casadio, A. et al., Cell, 99:221-237 (1999); Frey, U. andMorris, R. G., Nature, 385:533-536 (1997); Martin, K. C. et al., Cell,91:927-938 (1997); and Steward, O. et al., Neuron, 21:741-751 (1998)),with two well-known cellular mechanisms, mRNA translocation and local,activity-dependent regulation of translation (FIGS. 7A-7B) (Steward, O.and Schuman, E. M., Annu. Rev. Neurosci., 24:299-325 (2001)).

The present invention provides cell-based screening methods foridentifying a pharmaceutical agent which is capable of modulatingSTAUFEN function by screening for STAUFEN function. By “capable ofmodulating STAUFEN function” is meant to include pharmaceutical agentswhich can modulate STAUFEN function. In one embodiment, STAUFEN functionis screened by determining the level of STAUFEN protein expression(translation). As described herein, STAUFEN is transcriptionallyupregulated during memory formation. Accordingly, in this embodiment,STAUFEN protein expression can be determined by determining STAUFEN mRNAor protein production. In a second embodiment, STAUFEN function isscreened by determining the functional readout of STAUFEN. In thisembodiment, a functional readout of STAUFEN can be determined bydetecting (such as using an antibody) the translocation of the STAUFENinto dendrites or by determining the level of STAUFEN proteinproduction. A functional readout of STAUFEN can also be determinedindirectly by detecting and measuring downstream gene products regulatedby a staufen gene product. In a third embodiment, STAUFEN function isscreened by determining the change in distribution of neural granules inthe cells.

By “STAUFEN function” is meant the biological activity of STAUFEN, whichincludes subcellular translocation of various mRNAs and local regulationof various protein translations (“the STAUFEN pathway”). Biologicalactivity is understood to mean biological function or action. By“STAUFEN pathway function” is meant a set of gene products whichinteract with a staufen gene product and/or with each other to produceSTAUFEN function, particularly the subcellular translocation of mRNA andlocal regulation of protein translation.

In a particular embodiment, STAUFEN: :indicator fusion proteinconstructs are employed in cell-based screening methods for identifyinga pharmaceutical agent which is capable of modulating STAUFEN function.Thus, in one embodiment, a cell-based screening method for identifying apharmaceutical agent which is capable of modulating STAUFEN functioncomprises (a) introducing a pharmaceutical agent to be evaluated for itsability to modulate STAUFEN function into host cells (particularly cellsof neural origin) expressing a STAUFEN::indicator fusion protein (e.g.,STAUFEN::GFP fusion protein); and (b) determining STAUFEN function. In aparticular embodiment, the pharmaceutical agent is introduced into thecells after stimulation of the CREB pathway using forskolin. By CREBpathway is meant CREB-dependent gene expression. The STAUFEN functiondetermined in step (b) is compared to the STAUFEN function of the hostcells of step (a) to which the pharmaceutical agent has not beenintroduced (untreated host cells expressing STAUFEN::indicator fusionprotein) (control). A difference in STAUFEN function of the treatedcells relative to the STAUFEN function of the untreated cells identifiesthe pharmaceutical agent as one which modulates (or is capable ofmodulating) STAUFEN function.

In one embodiment, STAUFEN function is determined by detecting anddetermining the level of STAUFEN::indicator fusion protein expression(translation) (e.g., by detecting STAUFEN::indicator fusion protein mRNAor protein production). In a second embodiment, STAUFEN function isdetermined by detecting (such as using an antibody) the translocation ofthe STAUFEN::indicator fusion protein into dendrites or by determiningthe level of STAUFEN::indicator fusion protein production. In a thirdembodiment, STAUFEN function is determined indirectly by detecting andmeasuring downstream gene products regulated by a staufen gene product.In a fourth embodiment, STAUFEN function is determined by determiningthe change in distribution of neural granules in the cells.

In another embodiment, a cell-based screening method for identifying apharmaceutical agent capable of modulating STAUFEN function comprises(a) introducing a pharmaceutical agent to be evaluated for its abilityto modulate STAUFEN function into host cells of neural origin, saidcells expressing STAUFEN::indicator fusion protein; and (b) detectingthe translocation of the STAUFEN::indicator fusion protein intodendrites. In a particular embodiment, the pharmaceutical agent isintroduced into the cells after stimulation of the CREB pathway usingforskolin. A difference in translocation of STAUFEN::indicator fusionprotein into dendrites in the presence of a pharmaceutical agentrelative to its translocation in the absence of pharmaceutical agentidentifies the pharmaceutical agent as one which modulates (or iscapable of modulating) STAUFEN function.

Cells expressing a STAUFEN::indicator fusion protein can be produced byintroducing into host cells a DNA construct comprising (1) DNA encodinga STAUFEN::indicator fusion protein (e.g., STAUFEN::GFP fusion protein);and (2) a promoter sequence of a ubiquitously expressed gene, whereinthe promoter sequence is operably linked to the DNA encoding theSTAUFEN::indicator fusion protein. In a particular embodiment, the DNAconstruct is introduced into host cells, e.g., via a vector, whichcauses the fusion protein to be expressed in the cells. Expression ofthe STAUFEN::indicator fusion protein can be transient or stable. Asused herein, “a promoter sequence of a ubiquitously expressed gene”refers to a promoter sequence of a gene with widespread expression.Examples of ubiquitously expressed genes are known in the art andinclude the actin gene and the ELAV gene.

A vector, as the term is used herein, refers to a nucleic acid vector,e.g., a DNA plasmid, virus or other suitable replicon (e.g., viralvector). Viral vectors include retrovirus, adenovirus, parvovirus (e.g.,adeno-associated viruses), coronavirus, negative strand RNA viruses suchas orthomyxovirus (e.g., influenza virus), rhabdovirus (e.g., rabies andvesicular stomatitis virus), paramyxovirus (e.g. measles and Sendai),positive strand RNA viruses such as picomavirus and alphavirus, anddouble stranded DNA viruses including adenovirus, herpesvirus (e.g.,Herpes Simplex virus types 1 and 2, Epstein-Barr virus,cytomegalovirus), and poxvirus (e.g., vaccinia, fowlpox and canarypox).Other viruses include Norwalk virus, togavirus, flavivirus, reoviruses,papovavirus, hepadnavirus, and hepatitis virus, for example. Examples ofretroviruses include: avian leukosis-sarcoma, mammalian C-type, B-typeviruses, D-type viruses, HTLV-BLV group, lentivirus, spumavirus (Coffin,J. M., Retroviridae: The viruses and their replication, In FundamentalVirology, 3rd Edition, B. N. Fields, et al., eds., Philadelphia, Pa.:Lippincott-Raven Publishers) (1996)). Other examples include Sindbisvirus, murine leukemia viruses, murine sarcoma viruses, mouse mammarytumor virus, bovine leukemia virus, feline leukemia virus, felinesarcoma virus, avian leukemia virus, human T-cell leukemia virus, baboonendogenous virus, Gibbon ape leukemia virus, Mason Pfizer monkey virus,simian immunodeficiency virus, simian sarcoma virus, Rous sarcoma virusand lentiviruses. Other examples of vectors are described, for example,in McVey et al., U.S. Pat. No. 5,801,030, the teachings of which areincorporated herein by reference.

DNA encoding a STAUFEN: :indicator fusion protein can be manufactured asdescribed using methods known and described in the art (see, e.g.,Ausubel et al., Current Protocols In Molecular Biology (New York: JohnWiley & Sons) (1998); and Sambrook et al., Molecular Cloning: ALaboratory Manual, 2nd edition (New York: Cold Spring Harbor UniversityPress (1989)). DNA constructs comprising a promoter sequence operablylinked to DNA encoding a STAUFEN::indicator fusion protein can bemanufactured as described using methods known and described in the art(see, e.g, Ausubel et al., Current Protocols In Molecular Biology (NewYork: John Wiley & Sons) (1998); and Sambrook et al., Molecular Cloning:A Laboratory Manual, 2nd edition (New York: Cold Spring HarborUniversity Press (1989)). DNA constructs can be introduced into cellsaccording to methods known in the art (e.g., transformation, directuptake, calcium phosphate precipitation, electroporation, projectilebombardment, using liposomes). Such methods are described in moredetail, for example, in Sambrook et al., Molecular Cloning: A LaboratoryManual, 2nd edition (New York: Cold Spring Harbor University Press)(1989); and Ausubel, et al., Current Protocols in Molecular Biology (NewYork: John Wiley & Sons) (1998).

A vector, as the term is used herein, refers to a nucleic acid vector,e.g., a DNA plasmid, virus or other suitable replicon (e.g., viralvector). Viral vectors include retrovirus, adenovirus, parvovirus (e.g.,adeno-associated viruses), coronavirus, negative strand RNA viruses suchas orthomyxovirus (e.g., influenza virus), rhabdovirus (e.g., rabies andvesicular stomatitis virus), paramyxovirus (e.g. measles and Sendai),positive strand RNA viruses such as picomavirus and alphavirus, anddouble stranded DNA viruses including adenovirus, herpesvirus (e.g.,Herpes Simplex virus types 1 and 2, Epstein-Barr virus,cytomegalovirus), and poxvirus (e.g., vaccinia, fowlpox and canarypox).Other viruses include Norwalk virus, togavirus, flavivirus, reoviruses,papovavirus, hepadnavirus, and hepatitis virus, for example. Examples ofretroviruses include: avian leukosis-sarcoma, mammalian C-type, B-typeviruses, D-type viruses, HTLV-BLV group, lentivirus, spumavirus (Coffin,J. M., Retroviridae: The viruses and their replication, In FundamentalVirology, 3rd Edition, B. N. Fields, et al., eds., Philadelphia, Pa.:Lippincott-Raven Publishers) (1996)). Other examples include murineleukemia viruses, murine sarcoma viruses, mouse mammary tumor virus,bovine leukemia virus, feline leukemia virus, feline sarcoma virus,avian leukemia virus, human T-cell leukemia virus, baboon endogenousvirus, Gibbon ape leukemia virus, Mason Pfizer monkey virus, simianimmunodeficiency virus, simian sarcoma virus, Rous sarcoma virus andlentiviruses. Other examples of vectors are described, for example, inMcVey et al., U.S. Pat. No. 5,801,030, the teachings of which areincorporated herein by reference.

Anti-staufen antibodies can also be used to determine whether aparticular pharmaceutical agent has an effect on STAUFEN function, suchas by detecting translocation of STAUFEN protein, as described above.Anti-staufen antibodies can also be used to determine whether aparticular pharmaceutical agent has an effect on the levels of STAUFENprotein expression (translation) by detecting STAUFEN proteinproduction.

The present invention also encompasses methods of screening for oridentifying a pharmaceutical agent which is capable of modulatingSTAUFEN function comprising (a) introducing into host cells(particularly cells of neural origin) a DNA construct, wherein the DNAconstruct comprises (1) DNA encoding an indicator gene; and (2) astaufen promoter sequence operably linked to the DNA encoding theindicator gene; (b) producing a sample by introducing into host cellscomprising the DNA construct a pharmaceutical agent to be assessed forits ability to modulate STAUFEN function under conditions appropriatefor expression of the indicator gene; (c) detecting and determining thelevel of indicator gene product produced in the sample obtained in step(b); and (d) comparing the level of indicator gene product detected instep (c) with the level of indicator gene product detected in controlcells into which the pharmaceutical agent has not been introduced. Adifference in the level of indicator gene product in the sample obtainedin step (b) compared to the level of indicator gene product in controlcells identifies the pharmaceutical agent as one which modulates STAUFENfunction. By “staufen promoter sequence” is meant a promoter sequenceusually upstream (5′) of the coding region of the staufen gene, whichcontrols the expression of the coding region by providing recognitionand binding sites for RNA polymerase and other factors which may berequired for initiation of transcription.

DNA constructs comprising a promoter sequence operably linked to DNAencoding an indicator gene can be manufactured as described usingmethods known and described in the art. See, for example, Ausubel etal., Current Protocols In Molecular Biology (New York: John Wiley &Sons) (1998); and Sambrook et al., Molecular Cloning: A LaboratoryManual, 2nd edition (New York: Cold Spring Harbor University Press(1989).

The term “indicator gene”, as used herein, refers to a nucleic acidsequence whose product can be easily assayed, for example,calorimetrically as an enzymatic reaction product, such as the lacZ genewhich encodes β-galactosidase. Other examples of widely used indicatorgenes include those encoding enzymes, such as β-glucoronidase andβ-glucosidase; luminescent molecules, such as green fluorescent protein(GFP) and firefly luciferase; and auxotrophic markers such, as His3p andUra3p. See, e.g., Ausubel et al., Current Protocols In Molecular Biology(New York: John Wiley & Sons, Inc.), Chapter 9 (1998)).

As used herein, a cell refers to an animal cell. The cell can be a stemcell or somatic cell. Suitable animal cells can be of, for example,mammalian origin. Examples of mammalian cells include human (such asHeLa cells), bovine, ovine, porcine, murine (such as embryonic stemcells), rabbit and monkey (such as COS1 cells) cells. Preferably, thecell is of neural origin (such as a neuroblastoma, neuron, neural stemcell, etc.). The cell can also be an embryonic cell, bone marrow stemcell or other progenitor cell. Where the cell is a somatic cell, thecell can be, for example, an epithelial cell, fibroblast, smooth musclecell, blood cell (including a hematopoietic cell, red blood cell,T-cell, B-cell, etc.), tumor cell, cardiac muscle cell, macrophage,dendritic cell, neuronal cell (e.g., a glial cell or astrocyte), orpathogen-infected cell (e.g., those infected by bacteria, viruses,virusoids, parasites, or prions).

The cells can be obtained commercially or from a depository or obtaineddirectly from an animal, such as by biopsy.

The pharmaceutical agent can be introduced into host cells (particularlycells of neural origin) either alone or after stimulation of the CREBpathway using forskolin.

Pharmaceutical agents which modulate, or are capable of modulating,STAUFEN function are further screened to determine the effect of theagents on long term memory formation or to identify those agents capableof modulating long term memory. In one embodiment, the method comprises(a) administering to an animal (particularly a mammal) a pharmaceuticalagent which modulates, or is capable of modulating, STAUFEN function;(b) training the animal of (a) and a control animal of the same speciesto which the pharmaceutical agent has not been administered underconditions sufficient to produce long term memory formation in theanimals; (c) assessing long term memory formation in the animals trainedin step (b); and (d) comparing long term memory formation in the animalsassessed in step (c). A control animal is the basis for comparison inassessing results associated with administration of a pharmaceuticalagent to an experimental animal. The experimental and control animalsare comparable, e.g., same age, genetic makeup, basal STAUFEN function(i.e., STAUFEN function prior to treatment with the pharmaceuticalagent). A difference in long term memory formation assessed in theanimal treated with (administered) the pharmaceutical agent relative tothe long term memory formation assessed in the control animal identifiesthe pharmaceutical agent as one which has the ability to modulate longterm memory formation in the animal.

Pharmaceutical agents which modulate, or are capable of modulating,STAUFEN function are also screened to determine the effect of the agentson performance by an animal of a hippocampal-dependent cognitive task orto identify those agents capable of modulating performance of ahippocampal-dependent cognitive task by an animal. In one embodiment,the method comprises (a) administering to an animal (particularly amammal) a pharmaceutical agent which modulates, or is capable ofmodulating, STAUFEN function; (b) training the animal of (a) and acontrol animal of the same species to which the pharmaceutical agent hasnot been administered under conditions appropriate for performance bythe animals of a specified hippocampal-dependent cognitive task; (c)assessing performance of the hippocampal-dependent cognitive task by theanimals trained in step (b); and (d) comparing performance of theanimals assessed in step (c). The experimental and control animals arecomparable, e.g., same age, genetic makeup, basal STAUFEN function(i.e., STAUFEN function prior to treatment with the pharmaceuticalagent). A difference in assessed performance by the animal treated with(administered) the pharmaceutical agent relative to the assessedperformance by the control animal identifies the pharmaceutical agent asone which has the ability to modulate the performance by the animal ofthe specified hippocampal-dependent cognitive task.

The present invention also provides methods for screening apharmaceutical agent for its ability to modulate long term memoryformation in an animal and for assessing its effect on long term memoryin an animal. Preferably, the animal is an adult mammal. In oneembodiment, the method comprises (a) administering to a first animal apharmaceutical agent of interest; (b) determining STAUFEN function inthe animal administered the pharmaceutical agent in (a) relative toSTAUFEN function in a control animal of the same species as the firstanimal to which the pharmaceutical agent has not been administered; (c)selecting the pharmaceutical agent if the STAUFEN function determined in(b) differs from the STAUFEN function in the control animal; (d)administering the pharmaceutical agent selected in (c) to a secondanimal; (e) training the second animal administered the pharmaceuticalagent in (d) and a control animal of the same species as the secondanimal under conditions appropriate to produce long term memoryformation in the animals; (f) assessing long term memory formation inthe animals trained in step (e); and (g) comparing long term memoryformation in the animals assessed in step (f). The first and secondanimals can be of the same or different species. The first animal andthe corresponding control animal are comparable, e.g., same age, geneticmakeup, basal STAUFEN function (i.e., STAUFEN function prior totreatment with the pharmaceutical agent). Similarly, the second animaland the corresponding control animal are comparable, e.g., same age,genetic makeup, basal STAUFEN function (i.e., STAUFEN function prior totreatment with (administration of) the pharmaceutical agent). Adifference in long term memory formation assessed in the animal treatedwith the pharmaceutical agent relative to the long term memory formationassessed in the control animal identifies the pharmaceutical agent asone which has the ability to modulate long term memory formation in theanimal.

The present invention also encompasses methods for screening apharmaceutical agent for its ability to modulate STAUFEN function in ananimal and for assessing the effect of a pharmaceutical agent on STAUFENfunction in an animal. Preferably, the animal is an adult mammal. In oneembodiment, the method comprises (a) administering a pharmaceuticalagent of interest to the animal; and (b) determining STAUFEN function inthe animal obtained in (a) relative to STAUFEN function in a controlanimal of the same species to which the pharmaceutical agent has notbeen administered. The experimental and control animals are comparable,e.g., same age, genetic makeup, basal STAUFEN function (i.e., STAUFENfunction prior to treatment with the pharmaceutical agent). A differencein STAUFEN function determined in the animal treated with thepharmaceutical agent relative to STAUFEN function determined in thecontrol animal identifies the pharmaceutical agent as one having theability to modulate STAUFEN function in the animal.

The invention also relates to methods for screening a pharmaceuticalagent for its ability to modulate performance of a hippocampal-dependentcognitive task by an animal and for assessing the effect apharmaceutical agent on performance of a hippocampal-dependent cognitivetask by an animal. In a particular embodiment, the animal is an adultmammal. In one embodiment, the method comprises (a) administering apharmaceutical agent of interest to a first animal; (b) determiningSTAUFEN function in the animal administered the pharmaceutical agent in(a) relative to STAUFEN function in a control animal of the same speciesto which the pharmaceutical agent has not been administered; (c)selecting the pharmaceutical agent if the STAUFEN function determined in(b) differs from the STAUFEN function in the control animal; (d)administering the pharmaceutical agent selected in (c) to a secondanimal; (e) training the animal administered the pharmaceutical agent in(d) and a control animal of the same species as the second animal underconditions appropriate for performance by the animals of a specifiedhippocampal-dependent cognitive task; (f) assessing performance of thehippocampal-dependent cognitive task by the animals trained in step (e);and (g) comparing performance of the animals assessed in step (f). Thefirst and second animals can be of the same or different species. Thefirst animal and the corresponding control animal are comparable, e.g.,same age, genetic makeup, basal STAUFEN function (i.e., STAUFEN functionprior to treatment with the pharmaceutical agent). Similarly, the secondanimal and the corresponding control animal are comparable, e.g., sameage, genetic makeup, basal STAUFEN function (i.e., STAUFEN functionprior to treatment with the pharmaceutical agent). A difference inassessed performance by the animal treated with the pharmaceutical agentrelative to the assessed performance by the control animal identifiesthe pharmaceutical agent as one which has the ability to modulate theperformance by the animal of the specified hippocampal-dependentcognitive task.

As used herein, training can comprise one or multiple training sessionsand is training appropriate for long term memory formation or forperformance of the specified cognitive task. The pharmaceutical agentcan be administered before, during or after one or more of the trainingsessions. By “training” is meant cognitive training.

Training of mammals for long term memory formation is conducted usingmethods generally known in the art (see, e.g., Josselyn et al., Societyfor Neurosci., 24:926, Abstract 365.10 (1998); Guzowski et al., Proc.Natl. Acad. Sci. USA, 94:2693-2698 (1997); Lamprecht et al., J.Neuroscience, 17(21):8443-8450 (1997): Bourtchuladze et al., Cell,79:59-68 (1994); and Kogan et al., Curr. Biol., 7:1-11 (1996)). Trainingof mammals for performance of specified hippocampal-dependent cognitivetasks is conducted using methods generally known in the art (see, e.g.,Barnes, C. A. et al., In Brain and Memory: Modulation and Mediation ofNeuroplasticity, J. L. McGaugh et al. (Eds.), Oxford University Press,pp. 259-276 (1995); Jarrard, L. E., Behavioral Neural Biology, 60:9-26(1993); Moser, M. B. et al., Proc. Natl. Acad. Sci. USA,92(21):9697-9701 (1995); Chen, C. et al., Behav. Neurosci.,110:1177-1180 (1996); Frankland, P. W. et al., Behav. Neurosci.,112:863-874 (1998); Holland, P. C. and Bouton, M. E., Curr. Opin.Neurobiol., 9:195-202 (1999); Kim, J. J. et al., Behav. Neurosci.,107:1093-1098 (1993); Logue, S. F. et al., Behav. Neurosci., 111:104-113 (1997); and Squire, L. R., Psychological Review, 99:195-231(1992)).

Pharmaceutical agents (drugs), as used herein, are compounds withpharmacological activity and include inorganic compounds, ionicmaterials, organic compounds, organic ligands, including cofactors,saccharides, recombinant and synthetic peptides, proteins, peptoids,nucleic acid sequences, including genes, nucleic acid products.

Pharmaceutical agents can be individually screened. Alternatively, morethan one pharamaceutical agent can be tested simultaneously for theability to modulate long term memory formation and/or the ability tomodulate performance of a hippocampal-dependent cognitive task and/orthe ability to modulate STAUFEN function in accordance with the methodsherein. Where a mixture of pharmaceutical agents is tested, thepharmaceutical agents selected by the methods described can be separated(as appropriate) and identified by suitable methods (e.g.,chromatography, sequencing, PCR).

Large combinatorial libraries of pharmaceutical agents (e.g., organiccompounds, recombinant or synthetic peptides, peptoids, nucleic acids)produced by combinatorial chemical synthesis or other methods can betested (see e.g., Zuckerman, R. N. et al., J. Med. Chem., 37:2678-2685(1994) and references cited therein; see also, Ohlmeyer, M. H. J. etal., Proc. Natl. Acad. Sci. USA, 90:10922-10926 (1993) and DeWitt, S. H.et al., Proc. Natl. Acad. Sci. USA, 90:6909-6913 (1993), relating totagged compounds; Rutter, W. J. et al. U.S. Pat. No. 5,010,175; Huebner,V. D. et al., U.S. Pat. No. 5,182,366; and Geysen, H. M., U.S. Pat. No.4,833,092). The teachings of these references are incorporated herein byreference. Where pharmaceutical agents selected from a combinatoriallibrary carry unique tags, identification of individual pharmaceuticalagents by chromatographic methods is possible.

Chemical libraries, microbial broths and phage display libraries canalso be tested (screened) for the presence of one or more pharmaceuticalagent(s) which are capable of modulating long term memory formationand/or modulating performance of a hippocampal-dependent cognitive taskand/or modulating STAUFEN function in accordance with the methodsherein.

Pharmaceutical agents identified in accordance with the screeningmethods herein can be administered to an animal to modulate or enhancelong term memory formation or performance of a hippocampal-dependentcognitive task in accordance with the methods herein. Pharmaceuticalagents identified in accordance with the screening methods herein canalso be administered in the treatment of the animal with a defect inlong term memory formation that is associated with a defect in STAUFENor an animal with a defect in performance of a hippocampal-dependentcognitive task, wherein the defect is associated with a defect inSTAUFEN, in accordance with the methods herein.

As used herein, a defect in long term memory formation associated with adefect in STAUFEN can be a biochemical or developmental defect. Thedefect in STAUFEN is either a diminution in the amount of STAUFENproduced, a diminution in STAUFEN function of STAUFEN produced or both adiminution in amount of STAUFEN produced and a diminution in STAUFENfunction.

“Modulating”, as the term is used herein, includes induction,enhancement, potentiation, reduction, blocking, inhibition (total orpartial) and regulation. By “regulation”, as the term is used herein, ismeant the ability to control the rate and extent to which a processoccurs.

By “enhancing” or “enhancement” is meant the ability to potentiate,increase, improve or make greater or better, relative to normal, abiochemical or physiological action or effect. For example, enhancinglong term memory formation refers to the ability to potentiate orincrease long term memory formation in an animal relative to the normallong term memory formation of the animal. As a result, long term memoryacquisition is faster or better retained. Enhancing performance of ahippocampal-dependent cognitive task refers to the ability to potentiateor improve performance of a specified hippocampal-dependent cognitivetask by an animal relative to the normal performance of thehippocampal-dependent cognitive task by the animal. The term“hippocampal-dependent cognitive task” refers to a cognitive taskassociated with the hippocampal region of the brain.

In mammals, the hippocampus is essential for the initial consolidationof explicit, or declarative memory. For reviews, see Squire, L. R.,Psychological Review, 99:195-231 (1992); and Milner, B. et al., Neuron,20:445-468 (1998). In particular, various studies have suggested thatthe hippocampus plays a key role in spatial memory, such as Morris watermaze, Barnes circular maze, radial-arm maze, T-maze and Y-maze (O'Keefe,J. and Nadel, L., The Hippocampus As A Cognitive Map, Oxford UniversityPress (1978); Morris, R. G. M. et al., Nature, 297:681-683 (1992);Jarrard, L. E., Behavioral Neural Biology, 60:9-26 (1993); Moser, M. B.et al., Proc. Natl. Acad. Sci. USA, 92(21):9697-9701 (1995); O'Keefe,J., Hippocampus, 9:352-364 (1999); Burgess, N. et al., BiologicalCybernetics, 83:301-312 (2000); and Barnes, C. A. et al., In Brain andMemory: Modulation and Mediation of Neuroplasticity, J. L. McGaugh etal. (Eds.), Oxford University Press, pp. 259-276 (1995)), contextualconditioning (Phillips, R. G. and LeDoux, J. E., Behav. Neurosci.,106:274-285 (1992); Kim, J. J. et al., Behav. Neurosci., 107:1093-1098(1993); Logue, S. F. et al., Behav. Neurosci., 111:104-113 (1997); Chen,C. et al., Behav. Neurosci., 110:1177-1180 (1996); and Holland, P. C.and Bouton, M. E., Curr. Opin. Neurobiol., 9:195-202 (1999)), contextdiscrimination (Frankland, P. W. et al., Behav. Neurosci., 112:863-874(1998); McDonald, R. J. and White, N. M., Behav. Neurosci., 109:579-593(1995); and McDonald, R. J. and White, N. M., Hippocampus, 5(3):189-197(1995)) and trace conditioning (Kim, J. J. et al., Behav. Neurosci.,109:195-203 (1995); Buchel, C. et al., J. Neurosci., 19(24):10869-10876(1999); Clark, R. E. and Squire, L. R., Science, 280:77-81 (1998);McGlinchey-Berroth, R. et al., Behav. Neurosci., 111(5):873-882 (1997);and McEchon, M. D. et al., J. Neurophysiol., 86(4):1839-1857 (1998)).

STAUFEN can be an intact protein or a functional or biologically activeequivalent of intact STAUFEN protein. A functional or biologicallyactive equivalent of intact STAUFEN protein refers to a molecule whichfunctionally resembles (mimics) intact STAUFEN protein. A functional orbiologically active equivalent of intact STAUFEN protein need not havean amino acid sequence analogous to the amino acid sequences of thestaufen gene products described herein. For example, a functionalequivalent of intact STAUFEN protein can contain a “SILENT” codon or oneor more conservative amino acid substitutions, deletions or additions(e.g., substitution of one acidic amino acid for another acidic aminoacid; or substitution of one codon encoding the same or differenthydrophobic amino acid for another codon encoding a hydrophobic aminoacid). See Ausubel et al., Eds., Current Protocols In Molecular Biology(New York: John Wiley & Sons) (1997).

As used herein, the term “animal” includes mammals, as well as otheranimals, vertebrate and invertebrate (e.g., birds, fish, reptiles,insects (e.g., Drosophila species), mollusks (e.g., Aplysia).Preferably, the animal is a mammal. The terms “mammal” and “mammalian”,as used herein, refer to any vertebrate animal, including monotremes,marsupials and placental, that suckle their young and either give birthto living young (eutharian or placental mammals) or are egg-laying(metatharian or nonplacental mammals). Examples of mammalian speciesinclude humans and primates (e.g., monkeys, chimpanzees), rodents (e.g.,rats, mice, guinea pigs) and ruminants (e.g., cows, pigs, horses). Theanimal is preferably an adult animal.

The invention also relates to methods of modulating long term memoryformation in an animal. In a particular embodiment, the animal is anadult mammal. In one embodiment, the method comprises treating theanimal to modulate staufen-dependent protein expression. In a secondembodiment, the method comprises treating the animal to modulate STAUFENfunction. In a particular embodiment, the method comprises administeringto the animal an effective amount of a pharmaceutical agent whichmodulates STAUFEN function in the animal. In another embodiment, themethod comprises treating the animal to modulate STAUFEN proteinexpression. In a particular embodiment, the method comprisesadministering to the animal an effective amount of a pharmaceuticalagent which modulates STAUFEN protein expression in the animal.

The present invention also relates to methods of enhancing long termmemory formation in an animal, preferably an adult mammal. In oneembodiment, the method comprises treating the animal to modulatestaufen-dependent protein expression. In a second embodiment, the methodcomprises treating the animal to increase STAUFEN function relative tothe STAUFEN function in the animal prior to treatment. In a particularembodiment, treatment to increase STAUFEN function comprisesadministering to the animal an effective amount of a pharmaceuticalagent which increases STAUFEN function relative to STAUFEN function inthe animal prior to administration of the pharmaceutical agent. In asecond embodiment, the method comprises treating the animal to increaseSTAUFEN protein expression relative to STAUFEN protein expression in theanimal prior to treatment. In a particular embodiment, treatment toincrease STAUFEN protein expression comprises administering to theanimal an effective amount of a pharmaceutical agent which increasesSTAUFEN protein expression relative to STAUFEN protein expression in theanimal prior to administration of the pharmaceutical agent. In anotherembodiment, the method comprises administering to the animal aneffective amount of a STAUFEN molecule, STAUFEN analog, biologicallyactive STAUFEN fragment or STAUFEN fusion protein. In still anotherembodiment, the method comprises administering to the animal aneffective amount of a nucleic acid sequence encoding a STAUFEN molecule,STAUFEN analog, biologically active STAUFEN fragment or STAUFEN fusionprotein.

The present invention further provides methods for treating an animalwith a defect in long term memory formation associated with a defect inSTAUFEN. The animal is preferably an adult mammal. The defect in STAUFENis either a diminution in the amount of STAUFEN produced, a diminutionin STAUFEN function of STAUFEN produced or both a diminution in amountof STAUFEN produced and STAUFEN function of STAUFEN produced. In oneembodiment, the method comprises treating an animal with a defect inlong term memory formation associated with a defect in STAUFEN toincrease STAUFEN function relative to the STAUFEN function in the animalprior to treatment. In a particular embodiment, treatment to increaseSTAUFEN function comprises administering to the animal an effectiveamount of a pharmaceutical agent which increases STAUFEN functionrelative to STAUFEN function in the animal prior to administration ofthe pharmaceutical agent. In a second embodiment, the method comprisestreating an animal with a defect in long term memory formationassociated with a defect in STAUFEN to increase STAUFEN proteinexpression relative to STAUFEN protein expression in the animal prior totreatment. In a particular embodiment, treatment to increase STAUFENprotein expression comprises administering to the animal an effectiveamount of a pharmaceutical agent which increases STAUFEN proteinexpression relative to STAUFEN protein expression in the animal prior toadministration of the pharmaceutical agent. In a another embodiment, themethod comprises administering to an animal with a defect in long termmemory formation associated with a defect in STAUFEN a STAUFEN compoundsuch as exogenous STAUFEN, STAUFEN analog, biologically active STAUFENfragment or STAUFEN fusion protein. In another embodiment, the methodcomprises administering to an animal with a defect in long term memoryformation with a defect in STAUFEN a nucleic acid sequence encodingSTAUFEN, STAUFEN analog, biologically active STAUFEN fragment or STAUFENfusion protein.

The invention also relates to methods of modulating performance of ahippocampal-dependent cognitive task by an animal, preferably an adultmammal. In one embodiment, the method comprises treating the animal tomodulate staufen-dependent protein expression. In a second embodiment,the method comprises treating the animal to modulate STAUFEN function.In a particular embodiment, the method comprises administering to theanimal an effective amount of a pharmaceutical agent which modulatesSTAUFEN function in the animal. In another embodiment, the methodcomprises treating the animal to modulate STAUFEN protein expression. Ina particular embodiment, the method comprises administering to theanimal an effective amount of a pharmaceutical agent which modulatesSTAUFEN protein expression in the animal.

The present invention also relates to methods of enhancing performanceof a hippocampal-dependent cognitive task by an animal, preferably anadult mammal. In one embodiment, the method comprises treating theanimal to modulate staufen-dependent protein expression. In a secondembodiment, the method comprises treating the animal to increase STAUFENfunction relative to STAUFEN function in the animal prior to treatment.In a particular embodiment, treatment to increase STAUFEN functioncomprises administering to the animal an effective amount of apharmaceutical agent which increases STAUFEN function relative toSTAUFEN function in the animal prior to administration of thepharmaceutical agent. In another embodiment, the method comprisestreating the animal to increase STAUFEN protein expression relative toSTAUFEN protein expression in the animal prior to treatment. In aparticular embodiment, treatment to increase STAUFEN protein expressioncomprises administering to the animal an effective amount of apharmaceutical agent which increases STAUFEN protein expression relativeto STAUFEN protein expression in the animal prior to administration ofthe pharmaceutical agent. In another embodiment, the method comprisesadministering to the animal an effective amount of STAUFEN, STAUFENanalog, biologically active STAUFEN fragment or STAUFEN fusion protein.In another embodiment, the method comprises administering to the animalan effective amount of a nucleic acid sequence encoding STAUFEN, STAUFENanalog, biologically active STAUFEN fragment or STAUFEN fusion protein.

The present invention further provides methods for treating an animalwith a defect in performance of a hippocampal-dependent cognitive task,wherein the defect in performance is associated with a defect inSTAUFEN. The animal is preferably an adult mammal. The defect in STAUFENis either a diminution in the amount of STAUFEN produced, a diminutionin STAUFEN function of STAUFEN produced or both a diminution in amountof STAUFEN produced and STAUFEN function of STAUFEN produced. In oneembodiment, the method comprises treating an animal with a defect inperformance of a hippocampal-dependent cognitive task associated with adefect in STAUFEN to increase STAUFEN function relative to STAUFENfunction in the animal prior to treatment. In a particular embodiment,treatment to increase STAUFEN function comprises administering to theanimal an effective amount of a pharmaceutical agent which increasesSTAUFEN function relative to STAUFEN function in the animal prior toadministration of the pharmaceutical agent. In a second embodiment, themethod comprises treating an animal with a defect in performance of ahippocampal-dependent cognitive task associated with a defect in STAUFENto increase STAUFEN protein expression relative to STAUFEN proteinexpression in the animal prior to treatment. In a particular embodiment,treatment to increase STAUFEN protein expression comprises administeringto the animal an effective amount of a pharmaceutical agent whichincreases STAUFEN protein expression relative to STAUFEN proteinexpression in the animal prior to administration of the pharmaceuticalagent. In another embodiment, the method comprises administering to ananimal with a defect in performance of a hippocampal-dependent cognitivetask associated with a defect in STAUFEN a STAUFEN compound such asexogenous STAUFEN, STAUFEN analog, biologically active STAUFEN fragmentor STAUFEN fusion protein. In another embodiment, the method comprisesadministering to an animal with a defect in performance of ahippocampal-dependent cognitive task associated with a defect in STAUFENa nucleic acid sequence encoding STAUFEN, STAUFEN analog, biologicallyactive STAUFEN fragment or STAUFEN fusion protein.

The invention also relates to methods for modulating performance by ananimal, preferably an adult mammal, of cognitive tasks associated withnon-hippocampal regions of the brain where staufen gene expression isfound to occur, methods for treating a defect in performance by ananimal of cognitive tasks associated with non-hippocampal regions of thebrain where staufen gene expression is found to occur and methods forscreening a pharmaceutical agent for its ability to modulate performanceby an animal of cognitive tasks associated with non-hippocampal regionsof the brain where staufen gene expression is found to occur. Suchmethods are similar to the methods described herein for modulatingperformance by an animal of hippocampal-dependent cognitive tasks, fortreating a defect in performance by an animal of hippocampal-dependentcognitive tasks and for screening a pharmaceutical agent for its abilityto modulate performance by an animal of hippocamapl-dependent cognitivetasks.

STAUFEN analogs, or derivatives, are defined herein as proteins havingamino acid sequences analogous to the staufen gene products describedherein. Analogous amino acid sequences are defined herein to mean aminoacid sequences with sufficient identity of amino acid sequence of thestaufen gene product described herein to possess the biological activityor biological function or action of the staufen gene product, but withone or more “SILENT” changes in the amino acid sequence.

Biologically active STAUFEN fragments refer to biologically activepolypeptide fragments of STAUFEN and can include only a part of thefull-length amino acid sequence of STAUFEN, yet possess biologicalactivity of STAUFEN. Such fragments can be produced by carboxyl or aminoterminal deletions, as well as one or more internal deletions.

STAUFEN fusion proteins comprise STAUFEN as described herein, referredto as a first moiety, linked to a second moiety not occurring in theSTAUFEN protein. The second moiety can be a single amino acid, peptideor polypeptide or other organic moiety, such as a carbohydrate, a lipidor an inorganic molecule.

The present invention further encompasses biologically activederivatives or analogs of STAUFEN, referred to herein as STAUFEN peptidemimetics. These mimetics can be designed and produced by techniquesknown to those skilled in the art. See, e.g., U.S. Pat. Nos. 5,643,873and 5,654,276. These mimetics are based on staufen sequences. Staufensequences are readily available in the art (see, e.g., Shao, et al.,Neuron, 32:463-475 (2001); Wickham et al., Mol. Cell. Biol.,19(3):2220-2230 (1999); Buchner et al., Genomics, 62(1):113-118 (1999);Micklem et al., EMBO J., 19(6):1366-1377 (2000); Monshausen et al., J.Neurochem., 76(1):155-165(2001); Tang et al., Neuron, 32(3):463-475(2001); Falcon et al., Nucleic Acid Research, 27(11):2241-2247 (1999);and Kiebler et al., J. Neurosci., 19(1):288-297 (1999)). Peptidemimetics possess biological activity or biological function or actionsimilar to the biological activity or biological function or action ofthe corresponding peptide compound, but possess a “biological advantage”over the corresponding peptide inhibitor with respect to one, or more,of the following properties: solubility, stability and susceptibility tohydrolysis and proteolysis.

Methods for preparing peptide mimetics include modifying the N-terminalamino group, the C-terminal carboxyl group and/or changing one or moreof the amino linkages in the peptide to a non-amino linkage. Two or moresuch modifications can be coupled in one peptide mimetic. Examples ofmodifications of peptides to produce peptide mimetics are described inU.S. Pat. Nos. 5,643,873 and 5,654,276.

Increased STAUFEN protein expression or production can be achieved byadministration of an exogenous STAUFEN or, alternatively, by increasingproduction of the endogenous STAUFEN, for example by stimulating theendogenous gene to produce increased amounts of STAUFEN. In a preferredembodiment, suitable pharmaceutical agents, as described herein, can beadministered to the animal to stimulate the endogenous gene to produceincreased amounts of a functional STAUFEN, thereby increasing STAUFENfunction in the animal.

In some animals, the amount of STAUFEN being produced can be ofsufficient quantity, but the STAUFEN is abnormal in some way and, thus,cannot exert its biological effect. That is, the STAUFEN being producedhas diminished or no functional activity (i.e., no biological activity,function or action). In this instance, providing copies of normalstaufen genes to the animal using techniques of gene transfer well knownto those skilled in the art, can increase STAUFEN function orconcentration. In another embodiment, an exogenous STAUFEN, STAUFENanalog, biologically active STAUFEN fragment or STAUFEN fusion proteincan be administered to the animal.

Nucleic acid sequences are defined herein as heteropolymers of nucleicacid molecules. The nucleic acid molecules can be double stranded orsingle stranded and can be a deoxyribonucleotide (DNA) molecule, such ascDNA or genomic DNA, or a ribonucleotide (RNA) molecule. As such, thenucleic acid sequence can, for example, include one or more exons, withor without, as appropriate, introns, as well as one or more suitablecontrol sequences. In one example, the nucleic acid molecule contains asingle open reading frame which encodes a desired nucleic acid product.The nucleic acid sequence is “operably linked” to a suitable promoter.

A nucleic acid sequence encoding a desired STAUFEN, STAUFEN analog,biologically active STAUFEN fragment or STAUFEN fusion protein can beisolated from nature, modified from native sequences or manufactured denovo, as described in, for example, Ausubel et al., Current Protocols inMolecular Biology, (New York: John Wiley & Sons) (1998); and Sambrook etal., Molecular Cloning: A Laboratory Manual, 2nd edition (New York: ColdSpring Harbor University Press) (1989). Nucleic acids can be isolatedand fused together by methods known in the art, such as exploiting andmanufacturing compatible cloning or restriction sites.

Typically, the nucleic acid sequence will be a gene which encodes thedesired STAUFEN, STAUFEN analog or STAUFEN fusion protein. Such a geneis typically operably linked to suitable control sequences capable ofeffecting the expression of the STAUFEN, preferably in the CNS. The term“operably linked”, as used herein, is defined to mean that the gene (orthe nucleic acid sequence) is linked to control sequences in a mannerwhich allows expression of the gene (or the nucleic acid sequence).Generally, operably linked means contiguous.

Control sequences include a transcriptional promoter, an optionaloperator sequence to control transcription, a sequence encoding suitablemessenger RNA (mRNA) ribosomal binding sites and sequences which controltermination of transcription and translation. In a particularembodiment, a recombinant gene (or a nucleic acid sequence) encodingSTAUFEN, STAUFEN analog, biologically active STAUFEN fragment or STAUFENfusion protein can be placed under the regulatory control of a promoter,which can be induced or repressed, thereby offering a greater degree ofcontrol with respect to the level of the product.

As used herein, the term “promoter” refers to a sequence of DNA, usuallyupstream (5′) of the coding region of a structural gene, which controlsthe expression of the coding region by providing recognition and bindingsites for RNA polymerase and other factors which may be required forinitiation of transcription. Suitable promoters are well known andreadily available in the art (see, e.g., Ausubel et al., CurrentProtocols in Molecular Biology (New York: John Wiley & Sons, Inc.)(1998); Sambrook et al., Molecular Cloning: A Laboratory Manual, 2ndedition (New York: Cold Spring Harbor University Press (1989); and U.S.Pat. No. 5,681,735).

STAUFEN, STAUFEN analogs, biologically active STAUFEN fragments, STAUFENfusion proteins and pharmaceutical agents, as well as nucleic acidsequences encoding STAUFEN, STAUFEN analogs, biologically active STAUFENfragments or STAUFEN fusion proteins can be administered directly to ananimal in a variety of ways. In a particular embodiment, administrationis via transplant of neural tissue, e.g., by injecting neural cells intothe brain. Other routes of administration are generally known in the artand include intravenous injection including infusion and/or bolusinjection, intracerebroventricular, intrathecal, parenteral, mucosal,implant, intraperitoneal, oral, intradermal, transdermal (e.g., in slowrelease polymers), intramuscular, subcutaneous, topical, epidural, etc.routes. Other suitable routes of administration can also be used, forexample, to achieve absorption through epithelial or mucocutaneouslinings. STAUFEN, STAUFEN analogs, biologically active STAUFEN fragmentsand STAUFEN fusion proteins can also be administered by gene therapy,wherein a DNA molecule encoding a particular therapeutic protein orpeptide is administered to the animal, e.g., via a vector, which causesthe particular protein or peptide to be expressed and secreted attherapeutic levels in vivo.

A nucleic acid sequence encoding a protein or peptide (e.g., STAUFEN,STAUFEN analog, biologically active STAUFEN fragment or STAUFEN fusionprotein) can be inserted into a nucleic acid vector according to methodsgenerally known in the art (see, e.g., Ausubel et al., eds., CurrentProtocols in Molecular Biology, John Wiley & Sons, Inc., New York(1998); Sambrook et al., eds., Molecular Cloning: A Laboratory Manual,2nd edition (New York: Cold Spring Harbor University Press) (1989)).

The mode of administration is preferably at the location of the targetcells. In a particular embodiment, the mode of administration is tocells of neural origin. Cells of neural origin include neural stemcells, neuroblastoma cells and neurons.

STAUFEN, STAUFEN analogs, biologically active STAUFEN fragments, STAUFENfusion proteins and pharmaceutical agents, as well as nucleic acidsequences encoding STAUFEN, STAUFEN analogs, biologically active STAUFENfragments or STAUFEN fusion proteins can be administered together withother components of biologically active agents, such as pharmaceuticallyacceptable surfactants (e.g., glycerides), excipients (e.g., lactose),stabilizers, preservatives, humectants, emollients, antioxidants,carriers, diluents and vehicles. If desired, certain sweetening,flavoring and/or coloring agents can also be added.

STAUFEN, STAUFEN analogs, biologically active STAUFEN fragments, STAUFENfusion proteins and pharmaceutical agents, as well as nucleic acidsequences encoding STAUFEN, STAUFEN analogs, biologically active STAUFENfragments or STAUFEN fusion proteins can be administeredprophylactically or therapeutically to an animal prior to,simultaneously with or sequentially with other therapeutic regimens oragents (e.g., multiple drug regimens), including with other therapeuticregimens used for the treatment of long term memory defects, theenhancement of long term memory formation, the modulation of performanceof hippocampal-dependent cognitive tasks or the treatment ofhippocampal-dependent cognitive task performance defects. STAUFEN,STAUFEN analogs, biologically active STAUFEN fragments, STAUFEN fusionproteins and pharmaceutical agents, as well as nucleic acid sequencesencoding STAUFEN, STAUFEN analogs, biologically active STAUFEN fragmentsor STAUFEN fusion proteins, that are administered simultaneously withother therapeutic agents can be administered in the same or differentcompositions. Two or more different STAUFEN, STAUFEN analogs,biologically active STAUFEN fragments, STAUFEN fusion proteins, nucleicacid sequences, pharmaceutical agents or combinations thereof can alsobe administered.

STAUFEN, STAUFEN analogs, biologically active STAUFEN fragments, STAUFENfusion proteins, and pharmaceutical agents, as well as nucleic acidsequences encoding STAUFEN, STAUFEN analogs, biologically active STAUFENfragments or STAUFEN fusion proteins, can be formulated as a solution,suspension, emulsion or lyophilized powder in association with apharmaceutically or physiologically acceptable parenteral vehicle,carrier or excipient. Examples of such vehicles, carriers and excipientsare water, saline, Ringer's solution, isotonic sodium chloride solution,dextrose solution, and 5% human serum albumin. Liposomes and nonaqueousvehicles such as fixed oils can also be used. The vehicle or lyophilizedpowder can contain additives that maintain isotonicity (e.g., sodiumchloride, mannitol) and chemical stability (e.g., buffers andpreservatives). The formulation can be sterilized by commonly usedtechniques. Suitable pharmaceutical carriers are described inRemington's Pharmaceutical Sciences.

An effective amount of pharmaceutical agent, STAUFEN, STAUFEN analog,biologically active STAUFEN fragment, STAUFEN fusion protein or nucleicacid sequence is that amount, or dose, administered to an animal that isrequired to effect a change (increase or decrease) in STAUFEN proteinexpression or in STAUFEN function. The dosage administered to an animal,including frequency of administration, will vary depending upon avariety of factors, including pharmacodynamic characteristics of theparticular augmenting agent, mode and route of administration; size,age, sex, health, body weight and diet of the recipient; nature andextent of symptoms being treated or nature and extent of the cognitivefunction(s) being enhanced or modulated, kind of concurrent treatment,frequency of treatment, and the effect desired.

Pharmaceutical agents, STAUFEN, STAUFEN analogs, biologically activeSTAUFEN fragments, STAUFEN fusion proteins and nucleic acid sequencescan be administered in single or divided doses (e.g., a series of dosesseparated by intervals of days, weeks or months), or in a sustainedrelease form, depending upon factors such as nature and extent ofsymptoms, kind of concurrent treatment and the effect desired. Othertherapeutic regimens or agents can be used in conjunction with thepresent invention. Adjustment and manipulation of established dosageranges are well within the ability of those skilled in the art.

Once an effective amount has been administered, a maintenance amount ofa pharmaceutical agent, STAUFEN, STAUFEN analog, biologically activeSTAUFEN fragment or STAUFEN fusion protein, or nucleic acid sequenceencoding a STAUFEN, STAUFEN analog, biologically active STAUFEN fragmentor STAUFEN fusion protein, can be administered to the animal. Amaintenance amount is the amount of pharmaceutical agent, STAUFEN,STAUFEN analog, biologically active STAUFEN fragment or STAUFEN fusionprotein (or nucleic acid sequence encoding a STAUFEN, STAUFEN analog,biologically active STAUFEN fragment or STAUFEN fusion protein)necessary to maintain the change (increase or decrease) in STAUFENprotein expression or in STAUFEN function achieved by the effectivedose. The maintenance amount can be administered in the form of a singledose, or a series or doses separated by intervals of days or weeks(divided doses). Second or subsequent administrations can beadministered at a dosage which is the same, less than or greater thanthe initial or previous dose administered to the animal. Determinationof such amounts are well within the ability of those skilled in the art.

The present invention will now be illustrated by the following examples,which are not to be considered limiting in any way.

EXAMPLES Example 1 Staufen Expression In Mouse Hippocampus

A fragment of mouse staufen, from nucleotide 551 to 851 of sequenceAF061942 from the NCBI database, was amplified by polymerase chainreaction (PCR) and subcloned into a EcoRI site of a PCRII vector(InVitroGen).

Antisense probes were generated by cutting the PCRII subclone with SmaI,priming from the Sp6 promoter. Sense probes were generated by cuttingthe PCRII subclone with Bg1II, priming from the T7 promoter.

Brains of 8-10 week old male wild type C57B1/6 mice were surgicallyremoved and placed in liquid nitrogen. Brains were sliced on a cryostatat 16 um and allowed to air dry. Tissue sections then were subjected tothe following in situ hybridization protocol:

Day 1:

If sections from fixed brains were used, the sections were sent to theprehybridization washes step. If fresh-frozen brains (i.e., not fixed)were used, the sections were first fixed as follows:

Fixing Fresh-Frozen Sections:

-   -   Slides were immersed in 4% paraformaldehyde/1× PBS at 4° C. for        20 min. The sections were then sent to prehybridization washes.

Prehybridization Washes:

-   -   1. The slides were washed 2×5 minutes with 1× PBS (pH 7.4)    -   2. The slides were then washed 2×5 minutes with 1× PBS        containing 100 mM glycine, freshly made since it will        precipitate if made ahead of time.    -   3. The slides were then incubated 15 minutes with 1× PBS        containing 0.3% Triton X-100.    -   4. The slides were then washed 2×5 minutes with 1× PBS.

Permeabilization:

-   -   5. Pre-warmed TE buffer, pH 8.0 (100 mM Tris-HCl, pH 8.0, 50 mM        EDTA, pH 8.0) at 37° C. was used. The slides were incubated 20        minutes at 37° C. with TE buffer, pH 8.0, containing 1 μg/ml        Proteinase K (RNase-free).

Post-Fix:

-   -   6. The slides were incubated 5 minutes at 4° C. in 4%        paraformaldehyde/1× PBS.    -   7. The slides were then wash 2×5 minutes with 1× PBS.

Acetylation:

-   -   8. The slides were incubated and rocked 2×5 minutes with 0.1 M        triethanolamine (TEA) buffer, pH 8.0, containing 0.25% (v/v)        acetic anhydride which has been added immediately before        incubation.

Pre-Hybridization:

-   -   9. Slide hybridization chambers were placed over sections on        slide. Pre-hybridization buffer was pre-warmed (4×SSC, 50%        formamide) at 37° C. About 750 μl were pipetted in per slide.        The slides were incubated at 37° C. for 10 min. or more.

Hybridization:

-   -   10. Hybridization solutions were prepared using Ambion In Situ        Hyb Buffer (Ambion #8806G) and 0.5-1 μg of DIG-labeled riboprobe        per ml. Enough hyb buffer plus probe was prepared for about 750        μl per slide. These solutions were kept on ice.    -   11. Pre-hybridization buffer was removed with pipet and about        750 μl of hyb buffer plus probe was pipetted into hyb chamber.        The slides were laid out in a humid chamber. The humid chamber        was sealed tightly and the slides were incubated overnight at        42° C.        Day 2:

Posthybridization:

-   -   12. Slides were kept separated according to probe, removed from        the hyb chambers, then washed 2×15 minutes in 2×SSC, with        shaking at 37° C.    -   13. The slides were washed 2×15 minutes with 1×SSC, with shaking        at 37° C.    -   14. RNasing—At this point, slides with different probes could be        put together. NTE buffer (500 mM NaCl, 10 mM Tris, pH 8.0, 1 mM        EDTA, pH 8.0) to 37° C. was pre-warmed. Slides were incubated        for 30 minutes at 37° C. in NTE buffer containing 20 μg/ml RNase        A.    -   15. 0.1×SSC was prewarmed to 37° C. The slides were washed 2×30        minutes in 0.1×SSC, with shaking at 37° C.

Immunological Detection:

-   -   16. Slides were washed 2×10 minutes in Buffer 1 (100 mM        Tris-HCl, pH 7.6, 150 mM NaCl), with shaking at RT.    -   17. New hyb chambers were placed on slides, and blocking        solution was added (Buffer 1 with 2% normal sheep serum and 0.1%        Triton X-100) about 750 μl per slide. The slides were incubated        for 30 minutes in blocking solution.    -   18. The blocking solution was removed with pipet and about 750        μl of antibody solution (0.1% Triton X-100, 1% sheep serum,        1:1000 anti-DIG-alkaline phosphatase) was gently pipetted in.        The slides were placed in a humid chamber and either incubated        for 2 hours at room temperature (RT), or overnight at 4° C.    -   19. Hyb chambers were removed, then the slides were washed 2×10        minutes in Buffer 1 with shaking at RT.    -   20. The slides were incubated for 10 minutes in Buffer 2 (100 mM        Tris-HCl, pH 9.5, 100 mM NaCl, 50 mM MgCl₂).    -   21. The slides were incubated in color solution (1× NBT/BCIP, 1        mM levamisole) for 2-24 hours in the dark (NBT=4-nitro blue        tetrazolium chloride;        BCIP=5-bromo-4-chloro-3-indolyl-phosphate). When color        development was optimal, the color reaction was stopped by        incubating the slides in Buffer 3 (10 mM Tris-HCl, pH 8.0, 1 mM        EDTA, pH 8.0), then the slides were dipped in distilled water.        Counterstaining could be done on the slides using 0.1% Nuclear        Fast Red (in water), about 5 minutes incubation. The slides were        incubated 2×10 minutes in distilled water.

After mounting tissue, DIG-labeled sections were viewed with an Axioplan2 imaging microscope from Ziess for expression in the hippocampus andadjoining areas.

Staufen expression was detected throughout the hippocampus withantisense RNA probes. Expression also was detected in other regions ofthe brain. In particular, antisense RNA probe hybridized to cells in theCA1, CA3 and dendate gyrus regions. In contrast, sense (control) probesyielded no detectable signal. These results imply that interference withstaufen function vis RNA antisense injections into the hippocampus willdisrupt memory formation.

The following materials and methods were used in the work described inExample 2.

Animals and Surgery

Ten to twelve week old C57B1/6 male mice (Taconic Laboratory, N.Y.) wereused. Mice were housed in groups of four in standard mouse cages andkept in a 12:12 light-dark cycle and constant temperature (22° C.) in ahumidity and ventilation-controlled animal house. With the exception ofsurgery, training and testing times, the mice had ad lib access to foodand water. Animals were acclimatized to animal house environment for aweek before surgery. On a day of surgery, mice were anesthetized with 20mg/kg Avertin and implanted with a 26-gauge guide double cannula aimedat the dorsal hippocampus using a stereotaxic apparatus (KorfInstruments, Calif.; coordinates: P=1 mm; L=1.5 mm to a depth of 1-1.2mm; Franklin and Paxinos, The Mouse Brain In Stereotaxis Coordinates,Academic Press, San Diego, Calif. (1997)). After the end of surgery,animals were individually maintained in a cage with ad lib access tofood and water. Seven days after recovery from surgery, animals weretrained for contextual fear conditioning.

Fear Conditioning Experiments

The basic fear conditioning procedures and equipment remained asdescribed (Bourtchuladze, R. et al., Cell, 79:59-68 (1994); andBourtchouladze et al., Learn Mem., 5(4-5):365-374 (1998)). On thetraining day, the mouse was placed in the conditioning chamber (MedAssociates) for 2 minutes before the onset of unconditioned stimulus(US) of 0.5 mA, two seconds shock. For weak training, US was repeatedtwo times with a one minute inter-trial interval between shocks. Forstrong training, 5 USs were given. Training was automated and performedby computerized software package (Med Associates).

Thirty seconds after the end of the last trial, the mouse was returnedto its home cage. The conditioning chamber was cleaned with 75% ethanoland then with water. Contextual memory was tested four days aftertraining by scoring freezing responses. Freezing was assessed with asampling method. That is, 2 second observations were taken every 5seconds (Bourtchuladze, R. et al., Cell, 79:59-68 (1994); Bourtchouladzeet al., Learn Mem., 5(4-5):365-374 (1998); and Frankland, P. W. et al.,Behav. Neurosci., 112:863-874 (1998)). A mouse was determined to befreezing when it adopted a motionless posture, refraining from all butrespiratory movements.

For each training and drug-injecting procedure, an experimentally naïvegroup of animals was used. The observations were made by an experimenterunaware of the experimental treatment of the mice. In each experiment,both training and testing were videotaped. Experiments were analyzedwith an analysis of variance (ANOVA) and t-tests.

Drug and Oligodeoxynucleotide (OND) Infusion Procedures

Anisomycin (ANI) (Sigma) was dissolved in 0.9% saline, and the pH wasadjusted with 1 N HCl to 7.4. Control animals received injections ofsaline. Mice were injected in the hippocampus (62.5 μg/2 μl perhippocampus) immediately after training. Infusions were made through theguide cannula using a 33-gauge injection needle. The needle wasconnected via a polyethylene tube to a microsyringe fixed in the pump 11(Harvard Instruments). The entire infusion procedure took 2 minutes andanimals were freely moving during this time in the home cage.Experiments were replicated 2 times and for each training procedure, anexperimentally naïve group of animals was used (n=47 total).

Mouse antisense oligodeoxynucleotides (ODNs) directed against CREB mRNA(5′-T-s-g-s-g-s-T-C-A-T-T-T-g-T-T-A-C-C-g-s-g-s-T-s-g-3′) (SEQ ID NO:1)was used to disrupt hippocampal CREB protein levels. Control groupsreceived infusions of ODN of the same base composition but in randomizedorder (scrambled CREB:5′-g-s-T-s-C-s-T-g-T-A-g-T-C-g-A-T-C-T-A-T-s-g-s-g-s-T-3′) (SEQ IDNO:2). ODNs were administered into the hippocampus (2 nmol/2 μl perhippocampus) as described above for ANI-infusion. CREB ODNs were infused20 hours before training. Experiments were replicated 3 times and foreach training procedure, an experimentally naïve group of animals wasused (n=54 total).

Mouse antisense oligodeoxynucleotides (ODNs) directed against staufenmRNA (5-′g-s-g-s-g-s-C-T-T-A-T-A-C-A-T-T-g-s-g-s-T-s-T-3′) (SEQ ID NO:3)were used to disrupt hippocampal STAUFEN protein levels. Control groupsreceived infusions of ODN of the same base composition but in randomizedorder (scrambled staufen:5′-g-s-T-s-g-s-T-A-C-T-g-A-T-T-g-A-C-s-T-s-g-s-T-3′) (SEQ ID NO:4). ODNswere administered into the hippocampus (4 nmol/2 μl per hippocampus) asdescribed above for ANI-infusion. Staufen ODNs were infused repeatedly,3 times. The first infusion was made 44 hours before training. Thesecond infusion was made 15 hours before training. The third infusionwas made immediately after training. Experiments were replicated 3 timesand for each training procedure, an experimentally naïve group ofanimals was used (n=39 total).

Histology

After the end of the behavioral testing, 2 μl of a solution of 4%methylene blue was infused into the cannula. Animals were sacrificed andtheir brains were removed, frozen and then cut at −20° C. with cryostatfor histological localization of infusion cannula.

Example 2 STAUFEN and Long Term Memory Formation In Mice

Five training trials (5×; “strong” training) yields maximal levels oflong term memory, while two training trials (2×, “weak” training) yieldsless than half maximal levels (FIG. 1).

Partial knock down of CREB expression by injection of antisenseoligonucleotides into the hippocampus 20 hours before training reducedmemory induced by strong training to the levels produced by weaktraining (FIG. 2). CREB ODN-injected mice showed significantly lessfreezing responses than vehicle-injected mice when animals were trainedwith 5USs (65.1±4.3% and 44.2±6.3%, control- and CREB ODN-injected mice,n=14 and n=17, respectively; p<0.01) (FIG. 2). There was no significantdifference between CREB ODN- and vehicle-injected mice when mice weretrained with 2 USs, although freezing responses of CREB ODN-treated micewere less than controls (34±5.8% and 28.4±5.1%, n=11 and n=12,respectively, p=0.47). These results provided validation of“CREB-dependence” for the assay.

The prototypical type-IV phosphodiesterase inhibitor, Rolipram,administered immediately after training, significantly enhanced theamount of memory induced by weak training but had no effect on themaximal memory levels produced by strong training. These experimentsprovided further support for “CREB-dependence” for the assay (FIG. 3).

Protein synthesis inhibitor anisomycin (ANI), injected immediately aftertraining, blocked contextual memory (FIG. 4). ANI-injected mice showedsignificantly fewer freezing responses than vehicle-injected mice whenanimals were trained with 5USs (51.01±7% and 28.42±4.9%, control- andANI-mice, n=11 and n=13, respectively; p<0.01) or 2USs (32.7±4.4% and17.1±4.3%, control- and ANI-mice, n=10 and n=12, respectively; p<0.05).

Staufen antisense ODN treatments impaired 4-day retention in mice after5 US training (FIG. 5). Freezing responses of staufen-treated mice(42.8±6.6%, n=12) were significantly less (p<0.05) than vehicle-injectedmice (61±4.5%, n=10). There was no significant difference betweenstaufen- and vehicle-injected mice when mice were trained with 2 USs,although freezing responses of staufen-treated mice were less thancontrols (30±3.1% and 38.4±3.0%, n=10 and n=7, respectively, p=0.08).

Together, these results indicate that different training protocols—weakand strong training—recruit shared and distinct molecular processes forcontextual memory formation. Maximal levels of memory, induced withstrong training, require protein synthesis that is matched by arequirement of cAMP-signaling, CREB-dependent transcription and normalfunction of STAUFEN in the hippocampus (most likely in somata). Memoryinduced by weak training appears to recruit protein synthesis in CREB-and STAUFEN-independent fashion; perhaps, through local proteinsynthesis pools in dendrites.

The following materials and methods were used in the work described inExamples 3 to 5.

Behavioral Training and Genetic Strains

Olfactory associative learning was quantified by subjecting two-to-threeday old adult flies to a Pavlovian conditioning procedure (Tully, T. etal., Cell, 79:35-47 (1994); and Tully, T. and Quinn, W. G., J. Comp.Physiol. [A], 157:263-277 (1985)). Briefly, groups of about 100 flieswere exposed sequentially to one odor (CS+) paired with footshock andthen a second odor (CS−) without foot-shock. Spaced and massed trainedanimals received 10 such training sessions with a 15-minute restinterval between sessions in the case of spaced training. For DNA chipexperiments, animals were rapidly frozen immediately (t=0), six (t=6) or24 hours (t=24) after training. 10 massed training sessions arecompleted in 39 minutes, compared with 2 hours 51 minutes for 10 spacedtraining sessions. To control for this timing difference, all groups offlies were loaded into machines at the same time, but onset of massedtraining was delayed such that completion of both training regimens weresimultaneous. Groups experiencing massed training thus experienced thetraining context (including air current) for the same total duration asthe spaced-trained groups. During the test trial (FIG. 6), flies wereexposed simultaneously to the CS+ and CS− in a T-maze. After twominutes, flies were trapped in either T-maze arm, anesthetized andcounted. From this distribution, a performance index (PI) wascalculated, so that a 50:50 distribution (no memory) yielded a PI ofzero and a 0:100 distribution away from the CS+ yielded a PI of 100. PIswere distributed normally and, hence, were analyzed parametrically. ForDNA chip and QPCR follow up experiments, an isogenic white line(w¹¹¹⁸(isoCJ1)) (Yin, J. C. et al., Cell, 81:107-115 (1995)) was used.StauC8/stauD3 heteroallelic mutants were generated by crossingb,pr,stau^(C8)/Cy0 and cn,stau^(D3)/Cy0 flies.

Affymetrix Chip Hybridizations and Probe Preparation

Total cellular RNA was isolated from adult heads using Trizol reagent(Gibco-BRL manufacturer's protocol). Frozen tissue was dolfed in amortar and then dounce homogenized in Trizol using a glass homogenizer(5 ml Trizol/gram tissue). Biotinylated cRNA probes for Affymetrix chiphybridizations were generated according to Affymetrix protocols. Reversetranscription was carried out using an anchored oligo-DT primercontaining a T7 RNA polymerase sequence (5′-GGCCAGTGAATTGTAATACGACTCACTATAGGGA GGCGG-T₂₄-VN-3′) (SEQ ID NO:5). cRNA (10 μg)probes were resuspended in 200 μl hybridization solution: 0.1 mg/mlherring sperm DNA, 0.5 mg/ml acetylated BSA, 0.1 M MES (SigmaMES-hydrate and MES-sodium salt), 1.0 M NaCl, 0.01% Triton X-100.Hybridization reactions, labeling, and chip scanning were done accordingto Affymetrix protocols.

Statistical Analysis

“Average Difference” (AvDif) values for each gene from each chip wereobtained from Affymetrix software without regard to any other parametertherein. The following steps of data analysis then were performed:

-   -   1) For a given timepoint (N=10 chips for spaced and 10 chips for        massed), all AvDif values below 10 were eliminated from the        database (set to “missing values).    -   2) The remaining AvDif values on each chip were normalized to        the mean AvDif for all genes and chips,        ${NormAvDiff} = {{AvDif}_{ij} \times \frac{{Mean}\quad{AvDif}}{{Mean}\quad{AvDif}_{j}}\quad{for}\quad{gene}\quad i\quad{on}\quad{chip}\quad{j.}}$    -   3) All genes for which N=0 (because of eliminated values) for        spaced OR massed treatments were eliminated.    -   4) A BoxCox transformation was performed (Westfall, P. H. and        Young, S. S., Resampling-based Multiple Testing: Examples and        Methods for p-value Adjustment (New York: John Wiley & Sons,        Inc.) (1993)) on NormAvDif values, according to a two-way        analysis of variance (ANOVA) model with TREATMENT and GENE as        main effects and TREAT×GENE as the interaction term. This method        evaluates a family of transformations of        BoxAvDif=NormAvDif^(x),        where −1<X<1        to find the particular value of X that minimizes the Sums of        Squares Error (SSE) of the ANOVA model (Sokal, R. R. and        Rohlf, F. J., Biometry, 2nd edition (San Francisco: W. H.        Freeman) (1981)).    -   5) All genes for which N<3 for spaced OR massed treatments were        eliminated.    -   6) The Effect Size (ES) for each gene was calculated as:        ES=mean BoxAVDIF (spaced)−mean BoxAvDif (massed)    -   7) The statistical significance of each ES was determined via a        bootstrapping method with the critical value (alpha) set at        0.05.    -   8) For comparisons across different experiments (timepoints) ES        values were expressed as Standard Normal Deviates (StNDs) as        follows: ${StD} = \frac{{ES}_{i}}{{St}.{Dev}.{ES}}$        for genes i and where St.Dev is the standard deviation of the        mean ES.

Quantitative Polymerase Chain Reaction (QPCR)

RNA isolations were performed with Trizol (BRL) as for Affymetrix chipprobe preparation (see above) with the following modifications. Afterthe Trizol step, samples were treated with DNAaseI (Promega-5U persample) for 30 minutes (37° C.) and then were extracted withphenol/chloroform/iso-amyl alcohol (BRL), precipitated with ethanol andresuspended in DEPC-treated water. Reverse transcription reactions wereperformed using 2.5 μG RNA per reaction with an oligo dT primer usingTaqman reverse transcription reagents (Applied Biosystems). PCRquantification was performed using 10% of the above RT product perreaction on a 7,700 real-time PCR machine using (Perkin Elmer) and SYBRgreen PCR core reagents (Applied Biosystems) according to manufacturer'sprotocols. Prior to QPCR, all PCR products were verified by eitherrestriction mapping or automated sequencing. Gene specific primers hadthe following sequences: pum: 5′-TGTAGACATAGTCTGGGGTCCTC-3′ (SEQ IDNO:6) and 5′-AAGCAACAGCCATTGGGTCCAC-3′ (SEQ ID NO:7), dCREB2:5′-GCAACTCGTCGGCGGC ATC-3′ (SEQ ID NO:8) and 5′-CGCCGGGCCGTTGTACTTTGT-3′ (SEQ ID NO:9), rux: 5′-CCACTCTGATTCCGCCACTG-3′ (SEQ ID NO:10)and 5′-GCGTTGAATCCTCCTCGGTATC-3′ (SEQ ID NO:11), TBP:5′-GCGGCTGTGATTATGCGAAT-3′ (SEQ ID NO:12) and 5′-CATACTTTCTCGCTGCCAGTCTG-3′ (SEQ ID NO:13), slbo: 5′-CAGACTACCGATGCGAACA ACA-3′ (SEQID NO:14) and 5′-GTGCCTGAACTGGTGGTGTATCA-3′ (SEQ ID NO:15), gliotactin:5′-CGCCTTCTGGAGGCAATACT-3′ (SEQ ID NO:16) and5′-GCGATCTGTAGTGGCTCCTTG-3′ (SEQ ID NO:17). Expression levels werenormalized to Drosophila TBP transcript levels. TBP was confirmed as anunchanged control by comparing in excess of 100 RNA extractions eachafter spaced and massed training. Thus TBP was a false positive at t=6in these DNA chip experiments. All reactions were done in parallel usingat least 8 independent RNA isolations for each group, with each RNAisolate being assayed in triplicate.

Immunocytochemistry and Confocal Imaging

Whole mount immunolabeling of adult brains was performed according toChiang et al., 2001 (Chiang, A. S. et al., J. Comp. Neurol., 440:1-11(2001)) using a Rat-anti-PUM antibody originally tested for specificityusing Western blots from mutant animals (Sonoda, J. and Wharton, R. P.,Genes Dev., 13:2704-2712 (1999)). Briefly, dissected brains were fixedfor two hours in a room temperature vacuum and then overnight with 4%paraformaldehyde in PBS. Fixed tissue then was blocked for two days at4° C. in PBS containing 2% Triton-X and 10% normal goat serum (NGS) andthen successively incubated for 2 days each (with washing in between) at4° C. in PBS containing 1% Triton X, 0.25% NGS and (1) a polyclonal ratanti-pum antibody (Sonoda, J. and Wharton, R. P., Genes Dev.,13:2704-2712 (1999)) diluted 1/1000, (2) a biotinylated goat anti-mouseIgG (1:200) and (3) a strepavidin Cy5-conjugate (1 μg/ml, diluted 1000×from stock solution) in PBS containing 1% Triton-X. Next, tissue wastreated with RNAse (0.1 mg/ml) for one hour, stained overnight in NBD(0.435 mM) (Chiang, A. S. et al., J. Comp. Neurol., 440:1-11 (2001)),for 30 minutes in propidium iodide (0.00625 mg/ml) and then mounted inFOCUSCLEAR. Whole-mount brains were imaged with a Zeiss LSM 510 confocalmicroscope (Carl Zeiss, Jena), equipped with a 10× Fluor objective lens(N.A. 0.5, working distance 2000 μm) and a 40× C-Apochromat waterimmersion objective lens (N.A. 1.2, working distance 220 mm).

Example 3 Experimental Design and Statistical Analysis for DNAMicroarrays

Transcriptional responses to olfactory LTM are likely to occur in asmall subset of neurons of the adult brain. One brain region criticallyinvolved in olfactory learning and memory is the mushroom body (deBelle, J. S. and Heisenberg, M., Science, 263:692-695 (1994); Dubnau, J.et al., Nature, 411:476-480 (2001); Pascual, A. and Preat, T., Science,294:1115-1117 (2001); Zars, T. et al., Science, 288:672-675 (2000)),which consists of approximately 5,000 neurons or roughly 10% of thebrain. Since mRNA is extracted from whole heads, a significant reductionin the signal from transcripts responding to memory formation isexpected. Thus, a statistical method which optimizes the detection ofsmall-magnitude differences in transcript levels was developed asdescribed below.

The nalyot^(P1) mutation disrupts LTM and produces a two-fold reductionin the level of expression of ADF1, a transcription factor apparentlyinvolved in structural but not functional aspects of synaptic plasticity(DeZazzo, J. et al., Neuron, 27:145-158 (2000)). Thus, Adf-1 served asan internal positive control by comparing basal transcript levelsbetween control (wildtype) flies and nalyot mutants using a prototypeDrosophila DNA chip from Affymetrix containing 1,542 known, clonedgenes. An experimental design was employed that (i) balanced varioussources of variation across treatment groups (wildtype versus mutant)and (ii) increased the number of replicate chips to improve statisticalpower. Traditional parametric statistics were optimized to detectreliably the Adf-1 difference. The optimal method is as follows: (1)1,000 heads were used per RNA extract, thereby averaging any individualvariation (from genetic background or other epigenetic effects) and anybatch effects (from handling subgroups of animals on different days).(2) A minimum of 5 replicate chips (independent RNA extractions) wereused per treatment group. (3) “Avg-Diff” values less than 10 wereeliminated. (4) Avg-Diff values on each chip were normalized for smalldifferences in the amounts of probe used per chip. (5) A Box-Coxtransformation was applied to Normalized Avg-Diff values to minimize theexperiment-wide error variance (sums of squares error, SSE) and to yieldmore homogeneous error variances among groups (genes). (6) Statisticalsignificance for the effect size (ES; the difference between mean valuesfor wild-type versus mutant treatment) for each gene was determined viabootstrapping. (7) Effect sizes for all genes then were expressed as“standard deviates” (sdv; the effect size for a given gene expressed inunits of the standard deviation of all ESs (for all genes).

This method yielded a significant difference for expression of Adf-1transcripts between wildtype flies and nal^(P1) mutants (ES=2.8 sdv;N=5; P=0.002). The decrease in Adf-1 expression in nalyot mutant flieswas confirmed with real-time (quantitative) RT-PCR (QPCR; N=4 RNAextracts; P=0.001) and with Northern blots (N=12 RNA extracts; P=0.001).

Another gene on the chip, annotated as “CaSpeR-1” in the Affymetrixdatabase, expressed at significantly higher levels in nal^(P1) mutantsthan in wildtype flies (ES=−4.1 sdv.). The specific oligonucleotide(oligo) sequences on the chip corresponded to the “mini-white” eye colormarker gene contained within the PlacW transposon insertion of thenal^(P1) mutation (DeZazzo, J. et al., Neuron, 27:145-158 (2000)). Infact, the wildtype control flies (white¹¹¹⁸) carry a deletion of thisregion of the white gene. Hence, another internal control was detectedon the chip that is expressed in mutant flies but not in wildtypecontrol flies.

Overall, 68 of 1,542 genes showed statistically significant differencesbetween wildtype and nal^(P1) flies, with effect sizes (absolute values)ranging from 0.3 to 5.1. When ranking these effects from highest tolowest, the “CasPer-1” gene was fourth and Adf1 was sixth. The largesteffect size for the photolyase gene (FBgn0003082) was also confirmed viaNorthern blot analysis.

When compared to this parametric method, the traditional 2-fold approachdiffers in two important ways. First is the “denominator effect”: Amajority of candidates from the 2-fold method are relativelylow-expressing genes. This occurs because smaller effect sizes areneeded to yield a 2-fold change when the denominator of the ratio is asmaller number. Second is the “false negative effect”: A majority ofcandidates identified from the parametric method were higher-expressinggenes that were not detected by the 2-fold approach. This observationindicates that many biologically relevant changes in transcriptexpression levels might be missed with the traditional 2-fold method.This comparison is a relative one; each statistical method also has itsown implicit false-positive rate. Similar issues regarding thetraditional two-fold analysis have been echoed in emerging literature onthe statistical analysis of DNA microarray data (Jin, W. et al., Nat.Genet., 29:389-395 (2001); Schadt, E. E. et al., J. Cell. Biochem.,80:192-202 (2000); Van Der Laan, M. J. and Bryan, J., Biostatistics, 2:445-461 (2001); and Wolfinger, R. D. et al., J. Comput. Biol., 8:625-637(2001)).

Example 4 Identification of Candidate Memory Genes (CMGs)

Previous studies have yielded a genetic dissection of olfactory memoryformation in Drosophila (Tully, T. et al., Cell, 79:35-47 (1994);Dubnau, J. and Tully, T., Annu. Rev. Neurosci., 21:407-444 (1998);Tully, T., Proc. Natl. Acad. Sci. USA, 93:13460-13467 (1996); andWaddell, S. and Quinn, W. G., Annu. Rev. Neurosci., 24:1283-1309(2001)). Of particular relevance is the observation that thelong-lasting memory produced by spaced training (10 training sessionswith a 15 minute rest interval between each) is blocked when proteinsynthesis is inhibited (Tully, T. et al., Cell, 79:35-47 (1994)) or whenexpression of a CREB repressor transgene is induced (Yin, J. C. et al.,Cell, 79:49-58 (1994)). Both of these manipulations produce no effect onmemory after massed training (10 training sessions with no restintervals). These results indicate that the memory produced in normalflies after spaced training, above and beyond that after massedtraining, is critically dependent on (CREB-mediated) gene expression.Thus, comparing mRNA from wildtype flies subjected to spaced versusmassed training should identify transcriptional changes specific to LTM.For example, non-specific transcriptional effects produced by exposureto odors or foot-shock alone are likely to be present after both spacedand massed training, thereby yielding no differential effect.

To accomplish this DNA chip comparison, approximately 60,000 wild-typeflies were subjected to spaced or massed training in a balancedexperimental design using batches of approximately 100 flies pertraining run. One hundred batches of flies (10,000 individuals) werefrozen in liquid nitrogen at each of three time-points (t=0, 6 and 24hours) after spaced or massed training. These 100 batches of frozenflies were combined, heads were collected and then distributed randomlyinto 10 sets of approximately 1,000 to generate 10 independent RNAextracts (for each time point and training regimen). In this manner,potential variations among different training runs or among individualflies (because of genetic background differences or other epigeneticeffects) were averaged out leaving only the potential treatment effectsof spaced and massed training. These 10 replicate RNA extractions thenwere used to generate probes for hybridization to 10 independentAffymetrix DNA chips. Importantly, inclusion of 10 replicates in thisexperimental design ensured a proper sampling of variation derived fromseparate RNA extractions (which were estimated to be nearly 40 timesgreater than the variation due to replicate chip hybridizations usingthe same cDNA).

From these data, 129 candidate memory genes (CMGs) were identified usingthe statistical method described herein in Example 3: 47 from t=0, 26from t=6 and 58 from t=24 hour groups (two genes were significant at twotime points each).

False positives are inherent in all DNA chip experiments, regardless ofstatistical method. Hence, only a subset of these CMGs will prove to betrue positives. Follow-up QPCR assays can be done on independent samplesof RNA to identify true positives.

Most, if not all, genes are pleiotropic, with protein functions thatsubserve more than one biological process. For example, a cell cyclegene that functions as a kinase to regulate cytoskeletal elements duringmitosis also may phosphorylate different substrates in terminallydifferentiated neurons (Mendez, R. et al., EMBO J., 21:1833-1844(2002)). Thus, CMGs that initially do not appear to be involved inmemory formation, nevertheless, may participate in memory formation(Pinto, S. et al., Neuron, 23:45-54 (1999)).

Confirmation that a CMG is involved in memory formation rests with thedemonstration that in vivo modulation (disruption) of the gene altersthat process (with some specificity). To this end, the pum gene has beenidentified two independent times (a CMG both at t=0 and t=6) from abehavioral screen for memory mutants with defective one-day memory afterspaced training. Mutations in pum produce deficits in one-day memoryafter spaced training, and pum is transcriptionally regulated in normalflies during long-term memory formation. The former result constitutesconfirmation of pum as a CMG that was suggested by the DNA chipexperiments. The latter result indicates that pum participates in acellular process that is acutely required during memory formation in theadult.

Existing polyclonal antibodies (Sonoda, J. and Wharton, R. P., GenesDev., 13:2704-2712 (1999)) were used to determine the expression patternof PUM in the central nervous system (CNS) of normal adults.Immunolabeling with a polyclonal rat-anti-PUM antibody (Sonoda, J. andWharton, R. P., Genes Dev., 13:2704-2712 (1999)) decorates somaticregions of most neurons. PUM was found to be expressed broadly with acomplex subcellular distribution. The majority of PUM immunoreactivityis peri-nuclear, but significant punctate staining also is observed inneuropilar regions. For example, in the mushroom bodies, strong somaticstaining surrounds the nucleus of all intrinsic neurons (Kenyon cells).Weaker punctate expression is detected in the dendritic neuropil regionof the mushroom bodies (calyx). These observations suggest that PUM mayfunction widely in the CNS.

Similar results were obtained on 5 μM sections as well as in whole mountpreparations with a polyclonal rabbit-anti-PUM antibody (Sonoda, J. andWharton, R. P., Genes Dev., 13:2704-2712 (1999)), with or withoutpre-absorption against embryonic tissue.

First discovered in genetic screens for mutations affecting Drosophilaembryonic development, the pum gene is part of a pathway involved intranslational repression during posterior patterning and germlinedetermination (Johnstone, O. and Lasko, P., Annu. Rev. Genet.,35:365-406 (2001); and Palacios, I. M. and Johnston, D. S., Annu. Rev.Cell. Dev. Biol., 17:569-614 (2001)). Polarization of theantero-posterior axis of the oocyte involves microtubule-dependenttransport to the posterior pole of a large RNP complex known as a “polargranule”, containing nanos (nos) mRNA, as well as numerous additionalcomponents, including the CMGs staufen, oskar, mago nashi and faf.Localized nos message serves as a restricted source of NOS protein,which functions together with PUM to repress translation of severaltarget mRNAs. Other genetic components in xenopus or fly oocytes thatinteract with PUM/NOS to regulate translation include cytoplasmicpolyadenylation element binding protein (CPEB or orb in flies)(Nakahata, S. et al., J. Biol. Chem., 276:20945-20953 (2001)), CycB,cdc2 (as a dimer, the latter two show kinase activity whichphosphorylates orb, thereby targeting it for ubiquitin-mediateddegradation) (Mendez, R. et al., EMBO J., 21:1833-1844 (2002); andReverte, C. G. et al., Dev. Biol., 231:447-458 (2001)), theubiquitin-proteosome pathway and eIF4-E (the cap-binding protein).Phosphorylation of CPEB by aurora kinase also facilitates interaction ofeIF4-E with eIF4-G and the rest of the translation initiation complex(Stebbins-Boaz, B. et al., Mol. Cell., 4:1017-1027 (1999)). KnownPUM/NOS target mRNAs include CycB (Nakahata, S. et al., J. Biol. Chem.,276:20945-20953 (2001); and Asaoka-Taguchi, M. et al., Nat. Cell Biol.,1:431-437 (1999)) and sex lethal (Sxl) (Deshpande, G. et al., Cell,99:271-281 (1999)).

Both the DNA chip experiments described here and a complementarybehavioral screen for memory mutants (e.g., see Example 2) haveidentified several components of this pathway. In addition to pum, DNAchip analyses have yielded stau, mago, faf, orb and Sxl as CMGs.Moreover, another CMG, msl-2, is a known translational target of Sxl.Several other CMGs appear to be involved more generally in the cellularmachinery subserving RNA binding, regulation of translation andcytoskeletal function. Only one of these CMGs (pumilio) was identifiedusing the traditional 2-fold method of microarray analysis, therebyproviding some biological validation for this statistical method.

These findings are further convergent with those of the complementarybehavioral screen for memory mutants in which P element insertions havebeen identified in or near pum, oskar, eIF-5C, CycB and seven additionalgenes involved with RNA processing and cytoskeletal function. Thesefindings suggest that the cellular machinery involved in targeting mRNAsand locally regulating their translation during embryogenesis also maybe used by neurons during long term memory formation.

Example 5 Disruption of staufen After Training Interferes with Long TermMemory Formation In Drosophila

In vertebrate hippocampal neurons, STAUFEN protein is associated with alarge RNP complex known as a “neural granule” (Krichevsky, A. M. andKosik, K. S., Neuron, 32:683-696 (2001); Tang, S. J. et al., Neuron,32:463-475 (2001); Kiebler, M. A. et al., J. Neurosci., 19:288-297(1999); and Kohrmann, M. et al., Mol. Biol. Cell., 10: 2945-2953(1999)). Neural granules are thought to package newly transcribed mRNAswith translational repressors and ribosomal components. These RNPparticles then are transported via microtubules along dendritic shafts,where they appear to disassemble in response to specific postsynapticdepolarizations presumably to release their repressed mRNAs for local,activity-dependent translation of new proteins (Steward, O. and Schuman,E. M., Annu. Rev. Neurosci., 24:299-325 (2001); Krichevsky, A. M. andKosik, K. S., Neuron, 32:683-696 (2001); Tang, S. J. et al., Proc. Natl.Acad. Sci. USA, 99:467-472 (2002); and Aakalu, G. et al., Neuron,30:489-502 (2001)). Identification with DNA chips and a behavioralscreen (e.g., see Example 2) of multiple components of this cellularmachinery suggests the involvement during memory formation of neuralgranules in the delivery of CREB-dependent transcripts to recentlyactivated synapses. A direct prediction from this hypothesis is thatdisruption of staufen after training will interfere with long-termmemory formation.

To test this hypothesis, memory formation was assayed in atemperature-sensitive mutant of staufen (stau^(C8)/stau^(D3)) (Ephrussi,A. et al., Cell, 66:37-50 (1991); and Lehmann, R. and Nusslein-Volhard,C., Development, 112:679-691 (1991)). At the restrictive temperature(29° C.), stau^(C8)/stau^(D3) mutant embryos exhibit a strong mutantphenotype (a complete deletion of abdominal patterning, along with otherdefects). However, at permissive temperature (18° C.), only slightdefects in abdominal segmentation can be seen. Accordingly, when thesestau^(C8)/stau^(D3) mutants were raised at the permissive temperature,and then adults were subjected to spaced training, stored during theretention interval and tested for one-day memory all at permissivetemperature, memory scores were comparable to controls reared under thesame conditions (FIG. 6). In contrast, when these mutants were raised,trained and tested at permissive temperature but were transientlyshifted to restrictive temperature only during the retention interval,one-day memory was nearly abolished (FIG. 6). Importantly, thistransient disruption of staufen does not produce non-specific effects onlearning or on sensorimotor responses because performance levels aresimilar (P=0.92, N=6 PIs per group) in staufen mutants when they aretrained and tested at 18° C. (PI=41±5) or when they first are shifted to29° C. for one-day prior to training and testing immediately after beingreturned to 18° C. (PI=40±6). These latter controls rule out thepossibility that non-specific effects on sensorimotor responses to odorsor footshock underlie the observed defects in memory retention producedby this transient disruption of STAUFEN. Rather, these data demonstratean acute requirement for STAUFEN after training—during the consolidationof long-term memory.

The following materials and methods were used in the work described inExample 6.

Breeding of Mutant Strains

Transposon mutagenesis was carried out as described (Dura, J. et al., J.Neurogenet., 9:1-14 (1993)) with minor modifactions. A PGAL4 transposonor a PlacZ X-linked mutator was used to generate strains “A-D” and “E”,respectively, which carried homozygous, adult-viable transposoninsertions somewhere on the second or third chromosomes (autosomes). Atmaximum effort, 96 mutant strains were generated and screened each week.After N=5 experiment, those strains with reproducibly defective memory(see below) were outcrossed for at least five generations to theparental strain to equilibrate genetic backgrounds. For A-D strains,this parental strain was w¹¹¹⁸;Sp/CyO;Sb/TM3, Ser double-balancer stock,which itself had been outcrossed to our standard w¹¹¹⁸ (isoCJ1) stock.For E strains, the parental strain was w¹¹¹⁸ (isoCJ1) itself.

Behavioral Screen

Pavlovian olfactory conditioning: One to four day old adult flies wereplaced in dry food bottles the night before training and kept at 25° C.Environment-controlled rooms remained at a constant 25° C. with 70%humidity, and flies were trained/tested in the dark. During one trainingsession, a group of approximately 100 flies was exposed consecutively tooctanol (CS+) paired with footshock (US) and then to a methycyclohexanol(CS−) without footshock, piped through the training chamber in an aircurrent. For spaced training, flies were subjected to ten trainingsessions with a 15-minutes rest interval in between each. Flies thenwere placed in dry food vials overnight at 18° C. The next day,conditioning odor avoidance responses were assessed for two minutes in aT-maze, where the CS+ and CS− are delivered simultaneously on convergentcurrents of air. After testing, flies were trapped in their respectiveT-maze arms, anesthetized and counted. A performance index (PI) wascalculated so that a 50:50 distribution (no memory) yielded a PI of 0and a 0:100 distribution away from the CS+ yielded a PI of 100. For onecomplete experiment, a second group of 100 flies was trained with odor2as the CS+ and odor1 as the CS−, and the two resulting PIs were averagedfor an N=1.

One-day memory after spaced training was evaluated for mutant strains ina minimum of three passes. On the first pass, an N=1 was generated for astrain. If the resulting PI was ≦50% of normal (wild-type) levels, thenan N=4 PIs was generated in a second pass. [At the maximum effort, 96mutant strains were evaluated each week, and the 17 lowest-scoringstrains were chosen for the second pass; their scores still were ≦50% ofwild-type controls.] If the average PI≦70% of normal, then the strainwas outcrossed to equilibrate genetic backgrounds (see above),re-homozygosed, and a second N=4 PIs was generated in a third pass. Ifthe average PI again was ≦70%, then the strain was designated acandidate memory mutant, and task-relevant sensorimotor responses wereevaluated.

Sensorimotor Responses: Shock reactivity was carried out in the T-mazeaccording to (Tully, T. et al., Cell, 79:35-47 (1994)). Two copper gridswere attached to either arm while only one was electrified (60 V). PIswere calculated as above by designating the shocked T-maze arm as “CS+”.Olfactory acuity was carried out in the T-maze according to a previouslypublished procedure herein incorporated by reference (Tully, T. et al.,Cell, 79:35-47 (1994)). The relative avoidance of octanol versusmethylcyclohexonal (delivered at the concentrations used duringconditioning) was quantified for naïve flies. PIs were calculated asabove by arbitrarily designating one odor as “CS+”. A minimum of N=6 PIswere generated for each sensorimotor response. Sixty candidate mutantstrains yielded average PIs≧90% of wild-type controls and weredesignated as memory mutants. Two additional strains (D0107 and D0185)yielded average PIs for olfactory acuity <75%, with those for shockreactivity still ≧90%, of controls. These were designated olfactorymutants. In a similar fashion, two strains (E3029 and E3065) weredesignated shock reactivity mutants.

Learning: Memory retention immediately after a single training sessionalso was quantified in the 60 memory mutants. Average PIs were ≦90% ofcontrols for 10 strains; these strains were distinguished as “learning”mutants, rather than “memory” mutants, although the distinction issomewhat arbitrary.

Molecular Identification of Transposon Mutations

Plasmid rescue of transposons: Genomic DNA was isolated from homozygousmutant flies, digested to completion with one of several possiblerestriction enzymes (mainly EcoRI, SacI and XhoI) and “plasmid rescued”using standard protocols (Sullivan, W. et al. (Eds.), DrosophilaProtocols (Cold Spring Harbor Laboratory Press, Cold Spring Harbor)(2000)). Sequences were obtained by automated sequencing (ABI) using aprimer directed against the 3′ LTR of pGawB or PlacZ (5-CACTCGCACTTATTGCAAGCATACG-3′) (SEQ ID NO:18) and were compared to the FlyBaseannotated database of Drosophila genome sequence (6 Gelbart, W. M. etal., Nucleic Acids Res., 25:63-66 (1997)). In every successful case (57of 60), a unique genomic insertion site was determined. For two strains(D0264 and D0851), the DNA sequence appeared identical, but itcorresponded entirely to sequences internal to PGAL4. Consequently, agenomic insertion site(s) has not yet been identified for these strains.

“Dog-tagging”: To confirm the molecular identification of each genomicinsertion site and to identify each memory mutant unambiguously, a rapidPCR-based method was developed to detect the transposon insertion uniqueto each mutant strain. From the genomic sequence around the transposoninsertion site, three PCR primers were generated. The sequence of oneprimer corresponded to the (common) 5′ end of the transposon; thesequences of the other two primers then corresponded to genomic sequenceflanking the (unique) transposon insertion site. The PCR reaction thenwas run with all three primers. In each case, the choice of genomicprimer sequences was such that fragments of two discernable sizes werePCR-amplified. A “mutant” fragment appeared if genomic DNA contained theappropriate transposon insertion. Alternatively, “wild-type” fragmentappeared of genomic DNA did not contain the appropriate transposoninsertion (i.e., from wild-type flies or from an inappropriatetransposant strain). Flies (or populations) heterozygous (heterogeneous)for the appropriate transposon insertion were identified by the presenceof both the mutant and wild-type PCR fragment. Genomic DNA from a givenstrain was obtained with standard methods.

For PCR, one 1 μl of each genomic sample was added to a PCR tube, and 1μl of the appropriate primer was then added. The addition of 5 μl of PCRbuffer, 1.5 μl of magnesium chloride, 35.5 μl of distilled water, 1 μlof DNTP's, and 0.5 μl of Taq was added to all samples. Thirty rounds ofampflication were run at the appropriate annealing temperatures for eachprimer. The PCR samples were then electrophoresed on an 1% agarose gel.For initial characterizations, the appropriate bands (mutant andwild-type) were gel purified and restriction-digested to confirm thatthe amplified bands were of the expected sequence. Such dog-tagconfirmation was accomplished for all 57 strains described.

Northern Blot Analyses of CMGs

RNA was isolated (according to manufacturer's protocols) with Trizol(Gibco) from heads of four independent groups of flies for each strain.PolyA RNA was selected using oligo dT-magnetic beads (Dynal) accordingto the manufacturer's protocol. Northern blots were prepared usingstandard techniques (DeZazzo, J. et al., Neuron, 27:145-158 (2000)).Briefly, 5 μg of PolyA-RNA per sample were electrophoresed through a 1%agarose-formaldehyde gel using MOPS buffer. Gels were blotted onto nylonmembrane (Schleicher and Schuel). P-32 labeled probes were generated byrandom priming using PCR-fragments corresponding to each CMG (whicheither were sequenced or restriction digested to confirm the fidelity ofamplification).

Enhancer-Trap Reporter-Gene Histology of Memory Mutants

PlacZ: Freshly dissected brains from 2-5 day-old flies were fixed infreshly prepared 0.2% glutaraldehyde in PBS for 10 minutes on ice.Brains are washed 3× in PBS for 5 minutes each at room temperature (RT).Brains are incubated in XGAL staining solution (2 mg XGAL/1 ml XGALbuffer) in a moist, sealed container for 5 minutes to 48 hours at 37° C.Brains are post-fixed in 4% paraformaldehyde and 0.1% Triton-X 100 inPBS for 30 minutes in vaccuum at RT (allow air in and out several timesfor best results). Brains were cleared in FocusClear™; the FocusClear™bottle was kept in a hot water bath. Brains were mounted in MountClear™(from the hot-water bath). Whole-mount brains were photographed on aZeiss dissecting scope, using a SV11 objective.

PGAL4: Homozygous mutant females were bred to homozygous UAS-GFPS^(S65T)males (Bloomington stock #1521). The mushroom body enhancer trap strain,C747, was used as a positive control, while homozygous mutant females(no UAS-GFP) served as negative controls. Three-to-five day oldheterozygous female progeny were examined for GFP expression patterns.Flies were anesthetized with CO₂ and quickly dissected while pinned to aSylgard-covered dish and submerged in PBS. The proboscis was pushedcarefully into the extended position with fine forceps, a patch ofcuticle on the posterior of the proboscis was removed, and the largesilvery tracheae within the head capsule were carefully peeled out,avoiding damage to brain. The eyes to the level of the lamina were thencarefully removed and the brain was immaculately cleaned of all externaltracheae using two fine forceps. Brains were carefully transferred to 4%paraformaldehyde for 30 minutes, then to 4% paraformaldehyde +0.25%Triton-X100 for 30 minutes under mild vacuum. Brains were then clearedusing FocusClear™ solution (Pacgen, Vancouver, Canada) for 5 minutes,and then mounted in a drop of the same solution (Chiang, A. S. et al.,J. Comp. Neurol., 440:1-11 (2001)).

Whole-mount brains were imaged with a Zeiss LSM 510 confocal microscope(Carl Zeiss, Jena), equipped with a 10× Fluar objective lens (N.A. 0.5,working distance 2000 μm) and a 40× C-Apochromat water immersionobjective lens (N.A. 1.2, working distance 220 μm). Structures with GFPexpression were excited with a Kr/Argon laser at 488 nm, and theirfluorescence was detected after emissions had passed through a 505 nmlong-pass filter. Stacks confocal images were taken through the fullthickness of the central brain. The images were stored at a size of1024×1024 pixels. The distance between successive images (Z-axisdistance) was adjusted for the refractive index mismatch of the air andmounting medium as described previously (Chiang, A. S. et al., J. Comp.Neurol., 440:1-11 (2001)). In some cases, frontal and dorsal projectionswere rendered using Amira 2.3 (TGS, Inc., San Diego) after removingoptical slices between brain surface and mushroom bodies to betterreveal internal structures.

Example 6 Behavioral Screen for Memory Mutants

A large-scale behavioral screen for memory mutants was conducted one dayafter spaced training. The behavioral screen was initiated using agenetically engineered P element transposon (carrying a either a GAL4 orbeta-GALACTOSIDASE enhancer-trap reporter gene) as a mutator (Boynton,S. and Tully, T., Genetics, 131:655-672 (1992); and Dura, J. et al., J.Neurogenet., 9:1-14 (1993)). A total of 6,681 homozygous-viabletransposants were generated, each carrying (usually) a single P elementinsertion somewhere on the 2nd or 3rd chromosomes (which comprise about80% of the Drosophila genome). One-day memory after spaced training wasquantified for each strain. One hundred and six strains showed anaverage PI (performance index) ≦70% of wild-type control flies after atleast five generations of outcrossing to the genetic background ofwild-type control flies. Sensorimotor responses to the odors andfootshock used during Pavlovian training then were evaluated. Sixtystrains showed PIs ≧90% of wild-type control flies both for olfactoryacuity and for shock reactivity (cf. Dura, J. et al., J. Neurogenet.,9:1-14 (1993)). Thus, these 60 strains represent new mutants withbehavioral defects specific to the associative component of olfactorylong-term memory. These memory mutants were named after Pavlov's dogs.

Memory immediately after a single training session also was evaluatedfor these 60 memory mutants to judge whether “learning” was defectivealong with one-day memory after spaced training. The PIs of ten mutantswere <90% of wild-type controls, indicating defects in both initiallearning and in one-day memory after spaced training. Of the remaining50 mutants, 9 were judged “weak” memory mutants with PIs between 51% and70% of controls, while 41 were judged to be “strong” memory mutants withPIs≦50%. In the course of these genetic crosses and behavioral assays,it was discovered that three of the latter memory mutants werehomozygous-lethal but nevertheless yielded memory defects asheterozygotes.

Because the entire DNA sequence of the Drosophila genome now isavailable, it was possible to rapidly identify the molecular lesions for57 of these 60 mutant strains. These 57 lesions define 49 sites in theDrosophila genome. Twenty five of these sites lie within, and 24 liebetween, defined transcription units (genes), thereby identifying atotal of 70 new candidate memory genes (CMGs). Among these CMGs are fourgenes, oskar, CyclinB, eIF-5C and pumilio, which are known to beinvolved in the translocation of mRNA and regulation of translationduring embryogenesis. Significantly, pumilio and several other geneticcomponents (staufen, mago nashi, fat facets, orb, cdc2 and eIF2-G) ofthis cellular machinery also have been identified as transcriptionallyregulated genes during long-term memory formation in normal (wild-type)Drosophila. The milord, norka, avgust and krasavietz enhancer-trapmutations all show reporter-gene expression in adult mushroom bodies, asdo a majority of the other mutant strains. More interestingly, however,a few mutant strains show enhancer-trap patterns of expression outsideof mushroom bodies, thereby revealing novel regions of the adult centralnervous system that may be involved in olfactory memory formation.

Among the known genes, pumilio was identified twice in the behavioralscreen for memory mutants (milord-1 and -2). Significantly, pumilio alsowas identified from DNA chip experiments on wild-type flies as atranscriptionally regulated CMG at two different time-points (t=0 andt=6 hr) after spaced training. These results are fully complementary.Identifying memory mutants with transposon insertions in the pumiliotranscription unit confirms the gene as a “true positive” from the DNAchip experiments. Identifying pumilio in wild-type flies as atranscriptionally regulated gene during long-term memory formation showsthat the gene is actively involved in adult neural plasticity.

This initial convergence on pumilio has been reinforced by theobservation that additional genetic components of this pathway also havebeen identified from the behavioral screen and from the DNA chipexperiments. Genes that interact with pumilio have been described in thecontext of embryonic development. Together, they define a biologicalpathway involved with subcellular localization of mRNAs and localregulation of translation. Several of these interacting genes, includingstaufen, mago nashi, fat facets, orb, cdc2 and eIF-2G, have beenidentified from DNA chip experiments. Consistent with this result, threemore genetic components of this pathway—oskar, CyclinB and eIF-5C—wereCMGs from the behavioral screen for memory mutants (norka, avgust andkrasavietz, respectively).

The pumilio, oskar, CyclinB and eIF-5C genes are likely CMGs disruptedin milord-1/-2, norka, avgust and krasavietz memory mutants. Formilord-1/-2 and krasavietz, transposon insertions were found to residewithin the respective pumilio and eIF-5C transcription units, while thetransposons associated with norka and avgust reside near the CycB andoskar genes and disrupt their transcription. The pumilio, staufen, magonashi, fat facets, orb, cdc2 and eIF-2G genes, which are known tointeract with each other, were identifed directly from DNA chipexperiments as a transcriptionally regulated genes during long-termmemory formation. The discovery that mutations of pumilio yield defectsin one-day memory, as shown herein, constitutes strong initial proofthat pumilio is actively involved in long-term memory formation. Theobservation that multiple genetic components of this pathway have beenidentified cross-validates both the DNA microarray experiment and thebehavioral mutant screen for identifying genes associated with long-termmemory formation.

Convergence beyond the “pumilio pathway” and the “staufen pathway” alsois suggested from these two approaches. The mutant screen describedherein has identified several CMGs involved in ubiquitin-dependentprotein degradation, a cellular process already shown to participate inlong-term synaptic plasticity in Aplysia and in Drosophila (Hegde, A. N.et al., Cell, 89:115-126 (1997); and DiAntonio, A. et al., Nature, 412:449-452 (2001)). In Xenopus oocytes, local translation is controlled inpart via phosphorylation of cytoplasmic polyadenylation element bindingprotein (CPEB; orb is the fly homolog) by CDC2 kinase (Reverte, C. G. etal., Dev. Biol., 231:447-458 (2001)). To this end, DNA chip experimentsalso identified as a CMG fat facets (faf), a gene that is known tointeract with other members of the “pumilio pathway” or “staufenpathway”. The faf gene encodes a ubiquitin C-terminal hydrolase thatnegatively regulates proteolysis in several development contextsincluding the larval neuromuscular junction (DiAntonio, A. et al.,Nature, 412: 449-452 (2001); and Hochstrasser, M., Curr. Opin. Cell.Biol., 7:215-223 (1995)).

The teachings of all the articles, patents and patent applications citedherein are incorporated by reference in their entirety.

While this invention has been particularly shown and described withreferences to preferred embodiments thereof, it will be understood bythose skilled in the art that various changes in form and details may bemade therein without departing from the scope of the inventionencompassed by the appended claims.

1. a method of screening for or identifying a pharmaceutical agent capable of modulating staufen function comprising the steps of: a) introducing a pharmaceutical agent of interest into host cells expressing a STAUFEN::indicator fusion protein; and b) determining STAUFEN function, wherein a difference in the STAUFEN function determined in b) compared to the STAUFEN function of host cells of a) to which said pharmaceutical agent has not been administered identifies the pharmaceutical agent as one capable of modulating STAUFEN function.
 2. The method of claim 1, wherein STAUFEN function is determined by detecting and determining the level of STAUFEN::indicator fusion protein expression.
 3. The method of claim 1, wherein STAUFEN function is determined by detecting and determining the level of STAUFEN::indicator fusion protein mRNA produced.
 4. The method of claim 1, wherein STAUFEN function is determined by detecting and determining the level of STAUFEN::indicator fusion protein produced.
 5. The method of claim 1, wherein STAUFEN function is determined by detecting translocation of STAUFEN::indicator fusion protein into dendrites.
 6. The method of claim 1, wherein STAUFEN function is determined by measuring downstream gene products regulated by a staufen gene product.
 7. The method of claim 1, wherein STAUFEN function is determined by determining the distribution of neural granules in the cells.
 8. A method of screening a pharmaceutical agent for its ability to modulate long term memory formation in a mammal, comprising the steps of: a) administering to a mammal a pharmaceutical agent of claim 1 which modulates STAUFEN function; b) training the mammal of step a) and a control mammal of the same species to which said pharmaceutical agent has not been administered under conditions sufficient to produce long term memory formation in said mammal; c) assessing long term memory formation in the mammals trained in step b); and d) comparing long term memory formation in the mammals assessed in step c), wherein a difference in long term memory formation assessed in the mammal administered the pharmaceutical agent relative to long term memory formation assessed in the control mammal identified the pharmaceutical agent as one which capable of modulating long term memory formation in said mammal.
 9. The method of claim 8, wherein the animal is a rodent.
 10. A method of screening a pharmaceutical agent for its ability to modulate performance of a hippocampal-dependent cognitive task by a mammal, comprising the steps of: a) administering to a mammal a pharmaceutical agent of claim 1 which modulates STAUFEN function; b) training the mammal of step a) and a control mammal of the same species to which said pharmaceutical agent has not been administered under conditions sufficient for performance of a specified hippocampal-dependent cognitive task by the mammal; c) assessing performance of the hippocampal-dependent cognitive task by the mammals trained in step b); and d) comparing performance of the mammals assessed in step c), wherein a difference in performance of the specified hippocampal-dependent cognitive task by the mammal administered the pharmaceutical agent relative to performance of the cognitive task by the control mammal identifies the pharmaceutical agent as one which capable of modulating performance of the specified hippocampal-dependent cognitive task by the mammal.
 11. The method of claim 10, wherein the mammal is a rodent.
 12. A method of screening a pharmaceutical agent for its ability to modulate long term memory formation in a mammal, comprising the steps of: a) administering a pharmaceutical agent of interest to a first mammal; b) determining STAUFEN function in said mammal administered the pharmaceutical agent in step a) relative to STAUFEN function in a control mammal of the same species as said first mammal to which said pharmaceutical agent has not been administered; c) selecting the pharmaceutical agent if STAUFEN function determined in step b) differs from the STAUFEN function in said control mammal; d) administering the pharmaceutical agent selected in step c) to a second mammal; e) training said second mammal administered the pharmaceutical agent in step d) and a control mammal of the same species as the second mammal to which said pharmaceutical agent has not been administered under conditions appropriate to produce long term memory formation in the mammals; f) assessing long term memory formation in the mammals trained in step e); and g) comparing long term memory formation in the mammals assessed in step f).
 13. The method of claim 12, wherein said mammal has a defect in long term memory formation associated with a defect in STAUFEN function.
 14. The method of claim 12, wherein said mammal is a rodent.
 15. A method of screening a pharmaceutical agent for its ability to modulate performance of a hippocampal-dependent cognitive task by a mammal, comprising the steps of: a) administering a pharmaceutical agent of interest to a first mammal; b) determining STAUFEN function in said mammal administered the pharmaceutical agent in step a) relative to STAUFEN function in a control mammal of the same species a as the first mammal to which said pharmaceutical agent has not been administered; c) selecting said pharmaceutical agent if STAUFEN function determined in step b) differs from the STAUFEN function in said control mammal; d) administering the pharmaceutical agent selected instep c) to a second mammal; e) training said second mammal administered the pharmaceutical agent in step d) and a control mammal of the same species as the second mammal to which said pharmaceutical agent has not been administered under conditions appropriate for performance of a specified hippocampal-dependent cognitive task by the mammals; f) assessing performance of said hippocampal-dependent cognitive task by the mammals trained in step e); and g) comparing performance of said hippocampal-dependent cognitive task by the mammals assessed in step f).
 16. The method of claim 15, wherein said mammal is a rodent.
 17. A method of screening a pharmaceutical agent for its ability to modulate STAUFEN function in a mammal, comprising the steps of: a) administering a pharmaceutical agent of interest to said mammal; and b) determining STAUFEN function in said mammal administered said pharmaceutical agent in step a) relative to STAUFEN function in a control mammal of the same species to which said pharmaceutical agent has not been administered.
 18. The method of claim 17, wherein said mammal has a defect in long term memory formation associated with a defect in STAUFEN function.
 19. The method of claim 17, wherein said mammal is a rodent.
 20. A method of modulating long term memory formation in a mammal comprising modulating STAUFEN function in said animal.
 21. The method of claim 20, wherein long term memory formation is enhanced.
 22. The method of claim 20, wherein modulating STAUFEN function comprises administering to said mammal a pharmaceutical agent which modulates STAUFEN function in said mammal, in an amount effective to modulate STAUFEN function in said mammal.
 23. The method of claim 20, wherein said mammal is a rodent or a human.
 24. The method of claim 20 comprising modulating STAUFEN protein expression in said mammal.
 25. The method of claim 24, wherein long term memory formation is enhanced.
 26. The method of claim 24, wherein modulating STAUFEN protein expression comprises administering to said mammal a pharmaceutical agent which modulates STAUFEN protein expression in said mammal, in an amount effective to modulate STAUFEN protein expression.
 27. The method of claim 24, wherein said mammal is a rodent or a human.
 28. A method of treating a mammal with a defect in long term memory formation associated with a defect in STAUFEN comprising increasing STAUFEN function in said mammal relative to STAUFEN function in said mammal prior to said treatment.
 29. The method of claim 28, wherein increasing STAUFEN function comprises administering to said mammal a pharmaceutical agent which is capable of increasing STAUFEN function in said mammal, in an amount effective to increase STAUFEN function relative to STAUFEN function in said mammal prior to administration of said pharmaceutical agent.
 30. The method of claim 28, wherein said mammal is a rodent or a human.
 31. The method of claim 28 comprising increasing STAUFEN protein expression in said mammal relative to STAUFEN protein expression in said mammal prior to said treatment.
 32. The method of claim 31, wherein increasing STAUFEN protein expression comprises administering to said mammal a pharmaceutical agent which increases STAUFEN protein expression in said mammal, in an amount effective to increase STAUFEN protein expression relative to STAUFEN protein expression in said mammal prior to administration of said pharmaceutical agent.
 33. The method of claim 31, wherein said mammal is a rodent or a human.
 34. The method of claim 28 comprising administering to said mammal an effective amount of STAUFEN, STAUFEN analog, biologically active STAUFEN fragment or STAUFEN fusion protein.
 35. The method of claim 34, wherein said mammal is a rodent or a human.
 36. The method of claim 28 comprising administering to said mammal an effective amount of a nucleic acid sequence encoding STAUFEN, STAUFEN analog, biologically active STAUFEN fragment or STAUFEN fusion protein.
 37. The method of claim 36, wherein said mammal is a rodent or a human.
 38. The method of claim 36, wherein the nucleic acid sequence is incorporated into a viral vector.
 39. A method of modulating performance by a mammal of a hippocampal-dependent cognitive task comprising modulating STAUFEN function in said mammal.
 40. The method of claim 39, wherein performance by a mammal of a hippocampal-dependent cognitive task is enhanced.
 41. The method of claim 39, wherein modulating STAUFEN function comprises administering a pharmaceutical agent which modulates STAUFEN function in said mammal, in an amount effective to modulate STAUFEN function in said mammal.
 42. The method of claim 39, wherein said mammal is a rodent or a human.
 43. The method of claim 39 comprising modulating STAUFEN protein expression.
 44. The method of claim 43, wherein performance by a mammal of a hippocampal-dependent cognitive task is enhanced.
 45. The method of claim 43, wherein modulating STAUFEN protein expression comprises administering a pharmaceutical agent which modulates STAUFEN protein expression in said mammal, in an amount effective to modulate STAUFEN protein expression in said mammal.
 46. The method of claim 43, wherein said mammal is a rodent or a human.
 47. A method of treating a mammal with a defect in performance of a hippocampal-dependent cognitive task, said defect in performance associated with a defect in STAUFEN, comprising increasing STAUFEN function in said mammal relative to STAUFEN function in said mammal prior to said treatment, thereby resulting in treatment of said mammal.
 48. The method of claim 47, wherein increasing STAUFEN function comprises administering to said mammal a pharmaceutical agent which increases STAUFEN function in said mammal, in an amount effective to increase STAUFEN function relative to STAUFEN function in said mammal prior to administration of said pharmaceutical agent.
 49. The method of claim 47, wherein said mammal is a rodent or a human.
 50. The method of claim 47 comprising increasing STAUFEN protein expression in said mammal relative to STAUFEN protein expression in said mammal prior to said treatment.
 51. The method of claim 50, wherein increasing STAUFEN protein expression comprises administering to said mammal a pharmaceutical agent which increases STAUFEN protein expression in said mammal, in an amount effective to increase STAUFEN protein expression relative to STAUFEN protein expression in said mammal prior to administration of said pharmaceutical agent.
 52. The method of claim 50, wherein said mammal is a rodent or a human.
 53. The method of claim 47 comprising administering to said mammal an effective amount of STAUFEN, STAUFEN analog, biologically active STAUFEN fragment or STAUFEN fusion protein.
 54. The method of claim 53, wherein said mammal is a rodent or a human.
 55. The method of claim 47 comprising administering to said mammal an effective amount of a nucleic acid sequence encoding STAUFEN, STAUFEN analog, biologically active STAUFEN fragment or STAUFEN fusion protein.
 56. The method of claim 55, wherein said mammal is a rodent or a human.
 57. The method of claim 55, wherein the nucleic acid sequence is incorporated into a viral vector. 